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8ABSTRACT 
Colorectal cancer is the second most common type of cancer in the western world. 
Hereditary non-polyposis colorectal cancer (HNPCC) is the most common hereditary 
colorectal cancer syndrome. The estimation of HNPCC incidence has varied greatly, 
being 0.5-13% of all colorectal carcinomas. Non-polypotic cancers are considered to 
develope usually from polypotic precursor tumours. In that sense, the name of the disease 
is misleading. However, the number of polyps in HNPCC is usually not as high as in true 
polyposis syndromes. The names Lynch syndrome I and II are also options, especially 
because Lynch syndrome II includes also extracolonic forms of the disease. It is 
important to note that other organs like small intestine, urinary tract, kidney, stomach, 
biliary tract, and especially endometrium, may be affected, as well.  The majority of 
HNPCC is caused by mutations in MLH1 and MSH2 mismatch-repair genes. 
The aim of the study was to determine the incidence of MLH1- and MSH2-associated 
HNPCC and the population-based diagnostic screening strategy of colorectal cancer 
patients for HNPCC. In a two-phase study, 1044 colorectal cancer specimens were 
analyzed (Studies I and II). The tumours were removed from unselected newly diagnosed 
patients collected from 9 central hospitals in central, southern and eastern Finland, 
representing about 1/3 of the Finnish population. The tumour samples were fresh frozen. 
All the samples were analyzed for microsatelllite instability (MSI), caused by the 
replication error (RER), as MSI/RER is a characteristic feature of HNPCC tumours, 
allthough also about 15% of sporadic colorectal cancers are microsatellite-instable. All 
the patients were also tested for MSH2 and MLH1 mutations, MLH1 Finnish founder 
mutations included. There were 129 (12%) microsatellite-instable (MSI-H/MSI+) 
tumours. Of these, 28 had a germline mutation, corresponding to a 2.7% incidence of 
HNPCC.   
For HNPCC screening, three high-risk criteria were evaluated: 1) age under 50 years; 2) a 
previous or synchronous colorectal or endometrial cancer;   3) one first-degree relative 
with colorectal or endometrial cancer. Using these criteria, 96% of the HNPCC cases, 
with a MLH1 or MSH2 mutation, were detected.  
Also immunohistochemical staining methods were tested for diagnostic screening of 
HNPCC. In a large international collaborative study of 20 histopathological centers, 
different IHC staining protocols as well as different antibodies were evaluated (Study 
IIIA). According to that result, the International Collaborative Group of HNPCC (ICG-
HNPCC) recommends certain staining protocols and immunohistochemical antibodies of 
mismatch repair (MMR) proteins for diagnostic use. These recommended antibodies and 
staining protocols have been used for diagnostic purpose since the year 2000 at the 
Department of Pathology, Haartman Institute, Helsinki University Hospital (Study IIIB). 
Out of 174 studied paraffin-embedded tumour samples, 35 showed a loss of MMR 
expression. 32 out of 35 tumours were found to be MSI-positive. In the remaining 3 cases 
the MSI test result was not reliable because of the low proportion of tumour cells in the 
samples. As expected, the majority of the cases with a loss of MMR protein expression 
9was found by the MLH1 antibody. However, loss of expression was displayed also in 
MSH2 staining (8 cases) and MSH6 staining (3 cases). The result indicates that probably 
more MSH2 and MSH6 mutation-positive HNPCC patients and families will be detected 
by IHC, and genetic investigation can be directed to suspect an MMR gene according to 
IHC.
Several genetic events have been documented in colorectal tumour progression. Among 
these events, chromosome 18q21 losses have been seen frequently. Previously it has been 
suggested that DCC (deleted in colorectal cancer gene) mutation on 18q21 may have a 
major role in colorectal tumorigenesis. Since the DPC4/ SMAD4 gene is located near 
DCC on 18q21 we studied whether SMAD4 could have an important role in colorectal 
carcinogenesis (Study IV).  Among the unselected colorectal carcinomas, using 
monoclonal SMAD4 antibody, expression was absent in 20 out of 53 (38%) and reduced 
in another 15 (28%) cases. In conclusion, loss of SMAD4 protein seems to be more 
frequent occurrence in carcinogenesis than considered previously. The immunostaining
results of MSI tumours were strikingly different from the unselected carcinomas, as all 
MSI-H tumours displayed normal expression. It is understandable that in mutator 
phenotype tumours, loss of the SMAD4 gene does not play an important role, because 
both SMAD4 and TGF-β RII contribute their tumour-suppressive effects as members of 
the TGF-β signalling pathway. 
The cause of colorectal cancer is multifactorial. Tumour progression from a benign lesion 
to colorectal carcinoma is believed to follow a linear model, called the adenoma – 
carcinoma sequence. In this model a benign lesion becomes malignant by stepwise 
morphological and genetic changes in the epithelial cells of the colorectal mucosa.  
Microsatellite-instable (MSI-H) HNPCC tumours seem to develop according to this 
model, as well. In addition to the linear tumour progression model, there may also be 
some alternative ways. The hyperplastic polyp-serrated adenoma pathway seems to be 
one of these alternatives.  
The mismatch repair mechanism of DNA is affected in HNPCC tumour cells. The 
frequency of gene mutations in the colorectal tumours of HNPCC patients is therefore 
accelerated. The phenomenon has enabled estimation of the age of different histological 
cell populations of HNPCC tumours by using microsatellite markers in the same way as 
in human population studies, as a tumour clock (Study V). Stepvise deletions in 
noncoding polyA loci of HNPCC-tumours made it possible to estimate the moment of 
loss of mismatch repair (MMR), which seems to occur even before a "gatekeeper" 
mutation (Study VI). 
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REVIEW OF THE LITERATURE 
1. COLORECTUM 
The gastro-intestinal tract is involved in reducing food for absorption into the body. 
The colorectum is the largest part of the gastro-intestinal system. The proximal part of the 
colorectum is composed of the cecum, the ascending colon and  the transverse colon. The 
distal part of the colon is divided into the descending colon, the sigmoid colon and the 
rectum.  Colorectal mucosa consists of an epithelial cell layer and the lamina propria,
which are separated from the submucosa by a mucosal muscular layer. Innominate 
grooves increase the surface area of the mucosal surface. Multipotent stem cells are 
situated at the bottom of the crypts, and epithelial cells move upwards and proliferate 
along the sides of the crypts. The journey takes four to six days (Lipkin et al.,1963; 
Shorter et al.,1964; Potten and Loefler, 1990; Booth et al., 2002). The main cell types are 
absorptive cells and goblet cells, but there are a few neuroendocrine cells per crypt as 
well. Apoptosis takes place on the luminal surface, and the cells are shed into the 
colorectal lumen.
Estimations of the number of crypt stem cells vary from one to six or even more cells 
(Potten, Loeffler, 1990). If both daughter cells were to become stem cells, the number of 
stem cells would increase. However, in asymmetrical cell division of the stem cell, only 
one daughter cell remains a stem cell, while the other one differentiates and migrates 
upwards (Potten, Loeffler, 1990). Many authors support the idea that each adult crypt is 
derived from a single progenitor stem cell (Griffiths et al.,1988; Ponder et al 1985,). 
However, it has been shown(Yatabe et al., 2001) that multiple stem cells go through 
“bottlenecks” during their life-time. Each cell divides four to six times when migrating 
upwards to the mucosal surface. It has been shown in mice that the cell proliferation rate 
is higher in the lower part of the colonic crypt, namely for one to two days (Kellett et al., 
1992). Cell survival times are less well known in humans, but they are considered to be 
longer, about three to six days (Potten et al., 1992).  In each cell division, one enterocyte 
must go to apoptosis and the other one moves from the basement membrane to the 
colonic lumen. Programmed cell death, apoptosis, will accelerate when cell contact to the 
basement membrane is lost. 
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2.  PRECURSORS OF COLORECTAL CANCER 
Gastrointestinal epithelial cells proliferate rapidly. As epithelial cells have a short life-
time of about seven days (Potten and Booth, 1997) continuous, fast proliferation is 
needed. The fast proliferation makes the cells vulnerable to possible errors in replication 
and a target for the accumulation of various genetic mutations (Potten et al., 1988).  
Previous studies of cellular interaction have indicated that colonic adenomas and 
carcinomas are monoclonal (Ponder et al., 1986; Griffiths et al., 1988; Fearon et al., 
1987). Recent studies have shown polyclonality in adenomas, but monoclonality in the 
malignant process (Novelli et al., 1996; Merrit et al., 1997; Bjerknes et al., 1997).  
Analysis of Min (multiple intestinal neoplasia) mice revealed that normal intestinal crypts 
are monoclonal, whereas intestinal adenomas have a polyclonal structure. Within these 
polyclonal adenomas, all tumour lineages lose the wild type APC allele (Merritt et al., 
1997). Nevertheless there is still controversy about the clonality, and Siu et al. (1999) 
have studied dysplastic aberrant crypt foci by microdissection of the foci. They 
concluded that the identification of monoclonality in a precursor lesion indicates that the 
lesion is neoplastic.  
Epithelial cells proliferate and go to apoptosis at an equal rate in normal mucosa. The rate 
of apoptosis and proliferation is constantly altered during the neoplastic development. 
Traditionally, tumours are considered benign as long as the accumulated cells do not 
show evidence of invasive behaviour and maintain their original form, or they may 
become hyperplastic because of the low proliferation rate (Kinzler, Vogelstein, 1996; 
Risio et al., 1988).  
In colonic mucosa, dysplastic cells of adenoma are usually found at the luminal surface 
of the crypts. The cells at the bottom of the same crypts often appear to be 
morphologically normal. Dysplastic cells at the top of the crypts show alteration of the 
adenomal polyposis coli (APC) gene, as well as neoplasia-associated patterns of gene 
expression (Shih et al. 2001). Dysplasia is thought to be the first morphological step 
toward malignancy. The earliest neoplastic lesions are tiny aberrant crypt foci (Jen et al., 
1994). Dysplastic aberrant crypt foci or microadenomas are the precursors of adenomas 
(Kinzler, Vogelstein, 1996). However, hyperplastic polyps may carry an increased 
potential for dysplastic change, as seen in mixed hyperplastic polyposis (Longacre, 
Fenoglio-Preiser, 1990; Jass et al., 2000). Hyperplastic polyps were previously 
considered non-neoplastic (Pretlow et al., 1993), although, genetic alterations, such as K-
ras mutation, have been shown to be common in their epithelial cells, as well as clonality 
(Jen et al., 1994). Progression from a benign lesion to a malignant tumour possibly takes 
at least 10 years (Stryker et al., 1987). 
In addition to the linear tumour progression model above, there may also be some 
alternative ways. The serrated pathway seems to be one of these. It differs from a usual 
adenoma-carcinoma sequence, so that carcinoma associated with serrated adenoma, 
develops from a serrated polyp instead of a usual type of adenoma.  A large part of 
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sporadic MSI-cancers seem to develop in this way (Mäkinen et al. 2001) Especially, low 
microsatellite instability (MSI-L) is associated with the hyperplastic polyp-serrated 
adenoma pathway (Iino et al., 1999), as well as alteration of chromosome 1p (Bardi et 
al., 1993).
Morphologically there are different types of adenomas, i.e. tubular, villous or tubulo-
villous according their gland formation. The tubular adenomas are mostly pedunculated. 
The villous adenomas can be polypoid, flat or sometimes depressed (Kudo S, 1993).  
The serrated adenoma is a rare polypoid entity with a hyperplastic, serrated pattern of 
epithelia (Longacre and Fenoglia-Preiser, 1990; Mäkinen et al., 2001). As mentioned 
earlier, also a distinct serrated pathway to carcinoma has been described (Mäkinen et al., 
2001).
3. COLORECTAL CANCER 
Malignancy is followed by invasiveness and metastatic ability of the tumour cells, 
although genetic alterations have already taken place before morphological changes. In 
the colorectum, according to the TNM classification (WHO classification of tumours of 
the digestive system; Hamilton, Aaltonen, 1999; TNM atlas by International union 
against cancer UICC, 2002 edition) a tumour is considered malignant when it penetrates  
the muscularis mucosae into the submucosa. Until that point adenomatous changes in the 
epithelia are called mild or severe dysplasia. 
Four main classification systems are used for tumour staging in colorectal cancer (Figure 
1): Dukes classification by Dukes, 1932 and Kirklin et al., 1949 (Järvinen H, 1986), 
Astler and Coller, a modification of Dukes system by Astler and Coller, 1954 (Järvinen 
H. 1986), Turnbull modification of Dukes classification by Turnbull, 1967 (Järvinen H. 
1986) and TNM classification of the World Health Organisation. 
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Figure 1. The wall of the colorectum: Staging of colon cancer according to Turnbull 
modification of Dukes (A), Astler and Coller modification of Dukes classification (B) 
and TNM staging (C), respectively.  
Turnbull modification of Dukes:  
A   invasion from submucosa to muscle wall,  
B   invasion to serosa or perirectal fat 
C   regional lymph node metastasis  
D  distant metastases or invasion per continuotatem 
Astler and Coller modification of Dukes:
A    invasion to muscularis mucosae 
B1   invasion to muscle wall 
B2   invasion to serosa or perirectal fat 
C1   regional lymph node metastasis 
C2   invasion to mesenterial  tissue  
D    distant metastases or invasion per continuotatem 
TNM staging:
Stage   0  Tis N0 M0   
Stage   I   T1,T2 N0 M0 
Stage   IIA T3 N0 M0 
IIB T4 N0 M0 
Stage   IIIA T1,T2 N1 M0 
 IIIB T3,T4 N1 M0 
 IIIC AnyT N2 M0 
Stage  IV AnyT AnyN M1 
TNM classification:
TNM (T-primary tumor; N-regional lymph 
node; M-distant metastasis) 
T1 invasion to submucosa 
T2 invasion to muscle wall(muscularis 
propria)
T3 invasion through muscle wall to regional 
tissue
T4 invasion to other organs or structures 
N1 metastasis in 1 to 3 regional lymph nodes
N2 metastasis in 4 or more regional lymph
nodes 
M1 distant metastases
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4. GENETIC ALTERATIONS IN CANCER 
Cancer is a genetic disease. Environmental factors, like nutrition, may influence the 
development of cancer. A diet high in animal fat, or low in fiber content is associated 
with an increased risk for colorectal cancer (Willett et al., 1990; Ames et al., 1995; 
Diergaarde et al., 2003). At the cell level, accumulation of genetic alterations in the 
epithelial cells may lead to development of cancer by clonal selection (Nowell, 1978). 
Malignant cancer cells in the primary tumour are genetically heterogenous. Metastatic 
tumour cells carry genetic alterations needed for malignant phenotypes of tumour, like 
invasiveness and metastatic ability. The clonal expansion occurs through mutation in a 
single cell which has a selective growth advantage compared to the neighbouring cell 
populations (Nowell, 1978). 
Proto-oncogenes or cellular oncogenes control cell division. Alterations of genetic 
changes have been studied extensively in different types of malignant tumours. The 
mutation of oncogenes may lead to a disorder in the regulation of cell division, increased 
proliferation of cells, and to tumour formation. Oncogenes were first identified in 
retroviruses. The viral genes were seen to be able to induce tumour formation (Hampe et 
al., 1982). At the cellular level, oncogenes are dominant. This means that alteration of 
even one allele already is sufficient to cause activation of the gene. Only a few oncogenes 
are associated with familial cancer syndromes. Rearranged during transformation, the
RET oncogene is affected in the MEN2 syndrome (Eng, Mulligan, 1997), CDK4 in 
familial malignant melanoma (FMM) (de Snoo et al., 2003; Lynch et al., 2001) and MET
in hereditary papillary renal carcinoma (Schmidt et al., 1999).  
Tumour suppressor genes normally suppress cell division. Loss of normal function in 
both alleles leads to uncontrolled cell division and tumour growth. In contrast to the 
cellular oncogenes, in which a change in one allele will alter normal function, an altered 
suppressor gene does not lead to loss of function, as suppressor genes are recessive at the 
cellular level. For loss of gene function both alleles have to be mutated: this “two-hit 
hypothesis” was demonstrated by Knudson in 1971. The mutated genes in familial 
syndromes are mostly tumour suppressor genes (TSG). 
New genetic mechanisms have been recently included in carcinogenesis, most of all, 
epigenetic regulation of gene expression. The epigenetic factor changes the phenotype 
without altering the gene. Promoter hypermethylation, whichis associated with gene 
silencing, is especially well known (Villa et al., 2004). Epigenetic modification is also a 
major mechanism of MLH1 gene inactivation in sporadic colorectal microsatellite 
instable carcinomas (Kuismanen et al., 2000; Wheeler et al., 2000) and in DNA-
methylator phenotype tumours (Costello and Plass, 2001).  It has also lately become 
evident that some tumour suppressor genes, with a loss of only one allele, may contribute 
to carcinogenesis. The phenomenon is called haploinsufficiency (Cook and McCaw, 
2000; Rossi et al., 2002; Santarosa, Ashworth, 2004). In addition some other 
mechanisms, like “third hit” (Tomlinson et al., 2001), or extra allelic loss (Lamlun et al., 
1999) have been proposed. 
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Various tumour suppressor genes are alterated in carcinogenesis. TSGs are mainly 
divided into two groups, i.e. “gatekeeper” and “caretaker” genes. 
“Gatekeeper” genes initiate tumour growth or regulate cell proliferation as negative 
regulators. Such genes are APC, RB, VHL and TP53 in familial adenomatous polyposis 
(FAP)(Fodde et al., 2002), retinoblastoma (Knudson, 1971), and in the von Hippel-
Lindau (VHL)(Crossey et al., 1995) and the Li-Fraumeni syndromes (LFS)(Olivier et al., 
2003), respectively. 
“Caretaker” genes maintain genetic stability (Kinzler and Vogelstein, 1996). Mismatch 
repair genes (MMR), which are responsible for the HNPCC syndrome, are included in 
the caretakers. The genes responsible for xeroderma pigmentosa (XP)(Boulikas et al., 
1996) are also included in this group. The term “landscaper” gene (Kinzler, Vogelstein 
1996) has been used lately. This phenomenon is especially thought to have a role in 
hamartomatous colorectal tumours, for instance in Peutz-Jeghers polyps. The 
accumulation of mutations in somatic cells makes age-related penetrance understandable 
in most cancer types. Modifier and low penetrance genes have additional influence on 
tumorigenesis. 
5. SPORADIC COLORECTAL CANCER 
5.1. Altered genes in sporadic cancer 
Colorectal tumours are good objects for research. The tumours are easily visible in 
colonoscopy already in the early phases. Even the early molecular changes in epithelial 
cells can be monitored by microdissection of tiny lesions, and several genetic changes are 
demonstrated in cytogenetic analysis. The changes are mostly chromosomal losses, and 
chromosome regions 5q, 17p and 18q are frequently involved.  
A stepvise model for colorectal tumorigenesis, called adenoma – carcinoma sequence, 
was proposed by Kinzler and Vogelstein in 1996 (Figure 2 A). They demonstrated that at 
least seven somatic changes are needed for the initiation and progression of colorectal 
carcinoma. The APC gene is considered to act as a gatekeeper in colorectal 
carcinogenesis. The APC mutation initiates the adenomatous process at a very early 
phase, already in the dysplastic aberrant crypt foci (ACF) (Miyoshi et al., 1992; Powell et 
al.,1992; Smith et al.,1994; Nucci et al.,1997; Nascimbeni et al.,1999). Both alleles of the 
APC gene need to be inactivated for tumour progression. The APC gene acts as a typical 
suppressor gene. The APC gene was first mapped to chromosome 5 and identified at 
5q21 (Groden et al., 1991, 1993; Nishisho et al., 1991). The gene product is a part of the 
Wnt-signalling pathway (Bienz, Clevers, 2000). It binds to β-catenin and prevents the 
expression of C-MYC, which might be up-regulated in colorectal tumours (He et al., 
1998). 
Further mutations of other genes are needed for clonal expansion of the tumour. Some 
principles of the order of mutations are known, but their exact order in each individual 
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tumour is not known. The order and number of the mutations may nevertheless be crucial 
for the invasivenes of the carcinoma and the speed of the process (Shibata et al., 1993: 
Jen et al., 1994).   
Initial consequences of APC loss may reflect changes in cell fate due to the 
transcriptional activity of β-catenin / TCF4 (Bienz , Clevers, 2000). β-catenin is 
necessary for cadherin-mediated cell adhesion (Kemler R, 1993). APC can modulate such 
adhesion as part of its tumour-suppressing function. The second process involving APC
has been demonstrated by studies of Wingless (WG) and Wnt-signaling pathways in 
Drosophila, Xenopus and mouse. β -catenin and Armadillo (the Drosophila homologue of 
β-catenin) have been implicated as signal transducers in these pathways (Morel, Arias, 
2004). Point mutations in the K-RAS oncogene in 12p  occur in several types of human 
cancers, for instance pancreatic cancer, lung adenocarcinoma, and thyroid carcinoma. 
Oncogene amplification usually occurs late in tumour progression (Yokota et al.,1988). 
In colorectal tumour progression K-RAS mutation is, nevertheless an early event 
occurring in adenomas, but is also found often in hyperplastic polyps and in aberrant 
crypt foci (ACF)(Pretlow et al., 1993, 1992; Jen et al. 1994).
Normal 
epithelium
APC K-RAS DCC ;
DPC4/SMAD4
P 53
Dysplastic
ACF
Intermed 
adenoma
Early 
adenoma Carcinoma
Late
adenoma Metastasis
MMR
defect
Normal
epithelium
Hyperplastic 
polyp
?Normal 
epithelium
CarcinomaSerrated 
adenoma
Carcinoma
K-RAS
A
B
C
D
others
MMR defect?
Figure 2. Colorectal tumour progression. A)  A linear model of  the adenoma – carcinoma 
sequence B)  Hyperplastic polyp-serrated adenoma pathway C) Other possible carcinogenesis 
models D) A continuous effect of MMR deficiency.
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K-RAS mutations can take place in hyperplastic, non-atypical cells, as well as in 
dysplastic cells in early adenomas (Pretlow et al., 1993). The loss of chromosome 18q is 
a frequent event in colorectal tumorigenesis (Fearon, Vogelstein, 1990).  
Chromosome 17p loss is common in many types of malignancies, and mutations are seen 
in over 80% of colorectal cancers (Baker et al., 1990; Hollstein et al., 1991; Hsu et al., 
1991). The mutation is a late event of tumour progression. Loss of TP53 activity causes 
cell tolerance for DNA damage, and the inhibition of apoptosis, which leads to tumour 
growth. Losses at chromosomes 17p and 18q are also linked to invasiveness and    poor 
prognosis. 
In addition to the linear tumour progression model, there may be some alternative ways 
(Figure 2B and C). The hyperplastic polyp-serrated adenoma pathway (Figure 2B) seems 
to be one of these alternatives. It differs from a usual adenoma-carcinoma sequence, so 
that a carcinoma associated with a serrated adenoma develops from a hyperplastic polyp 
instead of a usual type of adenoma. K-RAS mutations are often involved in these 
hyperplastic polyps. A large part of sporadic MSI-cancers seem to develop in this way 
(Mäkinen et al., 2001). Propably there are still other alternative tumour progression 
pathways, which are not yet known (Figure 2C). 
5.2. DPC4/SMAD4 AND TGFß GENES IN COLORECTAL TUMORIGENESIS
Chromosome deletions are common genetic events in cancer. Previous studies have 
shown the loss of chromosome18q in over 60 % of colorectal cancers (Fearon et al., 
1990; Jen et al., 1994). The candidate tumour suppressor gene was localized on 
chromosome 18q21 and called DCC ( Figure 2A)  (deleted in colorectal cancer)(Hahn et 
al., 1996, Thiagalingam et al.1996). It has been shown that one copy of chromosome 18q 
is lost in 73 % of sporadic colorectal cancers and 47% of large adenomas with 
carcinomatous growth, but there are only few losses in less advanced adenomas 
(Vogelstein et al., 1988). 
It has been considered that the DCC gene mutation was the cause of malignant tumour 
progression (Cho et al., 1992; Hedrick et al., 1994; Peltomäki et al., 1991) Recently, 
however, a new candidate gene DPC4 (deleted in pancreatic cancer)/ SMAD4 at 18q was 
shown to be a possible target for alteration. The DPC4/SMAD4 tumour suppressor gene 
was first shown to be mutated in panceatic cancer (Hahn et al., 1995, 1996) and soon in 
colorectal tumours as well (Figure 2A) (Thiagalingam et al., 1996; Takaku et al., 1998). 
The frequency of DPC4/SMAD4 gene mutations was studied in other human cancers as 
well (Riggins et al., 1996, 1997) Immunohistochemistry has revealed the loss of 
expression of DPC4/SMAD4 protein (Wilentz et al., 2000; Takaku et al. 1999).  
SMAD genes (SMAD2, SMAD3 and SMAD4) play a key role in transforming growth 
factor-β signal pathways (Figure 3). The gene encodes human SMAD4 which is part of 
the TGF-β II signalling pathway (Moskaluk & Kern, 1996; Moskaluk et al.1997). TGF-β
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is a potent inhibitor of cell growth (Dai et al., 1999; Chiao et al., 1999), and TGF-β RII 
interacts with a TGF-β ligand. Tumours can become resistant to TGF-β by loss of 
function of one of the two receptors, or they can become inactivated through a mutation. 
SMAD4 arrests the cell cycle and induces apoptosis (Dai et al., 1999). 
As the genes DCC and DPC4/SMAD4 are located very near each other on chromosome 
18q21,  it is possible that loss of DPC4/SMAD4, rather than loss of DCC, causes tumour 
progression. In the study of Takaku et al. (1998), double-heterozygous mice for APC and 
SMAD4 mutations develop large intestinal tumours that exhibited hyperproliferation and 
invasive behaviour (Takaku et al., 1998). All these tumours showed loss of APC and 
SMAD4 alleles. The study suggested that in mouse intestinal tract, the loss of response to 
TGF-β receptor may lead to a malignant transformation of adenoma to carcinoma. 
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Figure 3. A simplified illustration of the TGF-β -SMAD4 signalling pathway from 
cell membrane to nucleus.
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6. HEREDITARY COLON CANCER 
There are inherited forms of colorectal cancer. For a long time these hereditary 
syndromes have been identified  by their clinical features, as well as by the histological 
structure of the tumour. The molecular background of the various syndromes has been 
increasingly documented (Eng & Ponder, 1993; de la Chapelle A 2003).  
6.1. POLYPOSIS SYNDROMES 
Adenomatous polyposis 
The familial adenomatous polyposis syndrome (FAP) is easily recognized in clinical 
practice because of its early onset and typical features. The APC adenomatous polyposis 
coli gene is mutated in the autosomal dominant disorder in which hundreds or thousands 
of adenomatous polyps develop already  at the patient´s  young age. The adenomatous 
polyps do not differ histologically from sporadic lesions. Without prophylactic surgical 
intervention, the risk of gastrointestinal cancer is very high (De Cosse et al., 1992). FAP 
patients may have extracolonic manifestations as well. There are numerous different 
types of mutations in the APC gene. The mutations occurring in the promoter area of the 
gene cause an attenuated form of FAP (AFAP) (Hernegger et al., 2002) in which the 
number of polyps may remain  under one hundred, and the prognosis of the disease is 
quite good. In variant forms of FAP the central nervous system (Turcot sdr; Anseline, 
1992; Hamilton et al., 1995) or other organs like the skin or bone (Gardner sdr; Axelsson 
et al., 1977) may be affected.  
Hamartomatous polyposis 
Peutz-Jeghers polyps have typical morphological features: hamartomatous polyps often 
appear in the small bowel, and their presence is noted because of their clinical symptoms. 
Large polyps often cause occlusion in the bowel and bleeding in the stool. The polyps are 
lobulated, and smooth muscle bundles form branches in the tumour. The tumours are 
usually sporadic. In the Peutz-Jeghers syndrome (PJS) the predisposing gene is LKB1
which encodes serine-threonine kinase (Hemminki et al. 1998). PJS entails an increased 
risk of malignancy, although the polyps are mainly benign. It has recently been 
demonstrated in the mouse model that there was no inactivation of the remaining wild-
type LKB1 allele in LKB1+/- associated polyps. The polyps in heterozygote animals 
nevertheless exhibited reduced LKB1 levels and activity, indicating that LKB1 was 
haploinsufficient for tumour suppression (Rossi et al., 2002).   
In another, large series of human PJ polyps showed high up-regulation of cyclo-
oxygenase-2 (COX-2) in the majority of the polyps. COX-2 is thus a potential target for 
chemoprevention in PJS patients (Rossi et al., 2002). 
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In juvenile polyps, only mild hamartomatous changes are seen. The tumours are small 
with some dilated glandular structures, and they are usually sporadic. In juvenile 
polyposis syndrome (JPS) multiple polyps are found in the gastrointestinal tract at a 
young age. The predisposing gene SMAD4/DPC4 responsible for JPS has been mapped 
to chromosome 18q (Howe et al., 1998; Bevan et al., 1999; Roth et al., 1999; Rothel et 
al., 1999). Even though polyps are generally nonmalignant, there is an increased risk of 
cancer in JPS. The risk of colorectal cancer is estimated to be as high as 10- 50% (Howe 
et al., 1998; Woodford-Richens et al., 2001). 
The Cowden syndrome (CS) is a rare autosomal dominantly inherited disorder in which 
benign lesions occur outside the gastrointestinal tract, but also hamartomatous polyps are 
present (Weinstock and Kawanishi, 1978). The diagnostic criteria for the syndrome have 
been confirmed by the International Cowden Consortium (Nelen et al., 1996).  The 
responsible gene PTEN was localized to chromosome 10q in CS family members (Nelen 
et al., 1996). 
MYH polyposis 
Inherited defects of the base excision repair gene MYH predispose to multiple colorectal 
adenomas and cancers (Enholm et al., 2003;Halford et al. 2003; Jones S et al. 2002, 
Lipton et al. 2003,). Tumors from affected persons displayed an excess of somatic 
transversions of a guanine-cytosine pair to a thymine-adenine pair (G:C - T:A) in the 
APC gene (Al-Tassan et al., 2002). Germ-line MYH mutations predispose persons to 
recessive phenotype, multiple adenomas, or polyposis coli. Genetic testing of MYH is 
indicated if in a person with multiple colorectal adenomas, but no identified APC or 
MMR gene mutation. 
.
6.2. HEREDITARY NON-POLYPOSIS COLORECTAL CANCER (HNPCC) 
6.2.1.  History  
Alfred Warthin was the first to desribe an inherited cancer family, “ family G” in 1913 
(the archives of internal medicine) by investigating 3600 clinical diagnostical and 
autopsy neoplastic tumour samples collected in the years 1895-1913 in the pathological 
laboratory  of the University of Michigan. The cancer family “ G” was re-examined and 
decribed by Henry T Lynch and Anne J Krush in 1971 (Cancer). Family “ G” was re-
evaluated and new families were incluled to the study. The cancer family syndrome was a 
natural name for the disease with an increased number of cancers clustered in family 
members. Later, the syndrome was called  Lynch syndrome I and Lynch syndrome II, 
after Henry T Lynch. In Lynch syndome I, only the colorectum is affected, whereas in 
Lynch syndrome II also extracolonic lesions occur. At the same time, also the name 
hereditary non-polyposis colorectal cancer (HNPCC) was taken into wide use (Lynch 
HT, 1988; Vasen et al.,1991). The first epidemiological study was published in 1986 in 
Finland by Jukka-Pekka Mecklin and Heikki Järvinen (1986,1987), who also established 
22
the Finnish HNPCC-Registry. More population-based studies have been carried out and 
clinical findings have been confirmed (Ponz de Leon et al., 1993; Benatti et al.,1993). 
    
6.2.2.  Incidence 
HNPCC is considered to be the most common colorectal hereditary cancer syndrome. It 
is an autosomal dominantly inherited disease. Estimates of its incidence have varied 
greatly. The previous estimates were very high, whereas some of the later studies have 
considered HNPCC to be even less common than FAP (Bodmer et al., 1994).  It is 
estimated that in 0.5 - 13 % of all colorectal cancers, an inherited genetic alteration is 
involved (Cannon-Albright et al., 1988; Houlston et al., 1992; Aaltonen et al., 1994; 
Bodmer et al., 1994), having been 1 - 5% in the recent studies (Ponz de Leon et al., 1993; 
Rodriguez-Bigas et al., 1997; Percesepe et al., 1999).  Considerable geographic clustering 
is also possible. Some variation in incidence has been noted in different geographical 
areas even within the same country (Modica et al., 1995). Dietary habits as well as other 
environmental factors may influence the incidence. Founder mutations are probably one 
reason for the clustering of cancer cases in certain geographic areas. 
6.2.3.  Clinical features 
Certain clinical features of HNPCC or Lynch syndrome have been described. The 
occurrence of metachronous or synchronous tumours, especially at a relatively young age 
(under 50 years) is a characteristic feature. The affected organ in HNPCC is mainly the 
colorectum. The tumours are located more often on the right side than on the left side (i.e. 
60 % vs. 40%), whereas in sporadic cases they are located mainly in the distal section of 
the large intestine. Although the tumours are often poorly differentiated, the prognosis is 
better than in sporadic carcinomas (Lynch et al., 1988; 1996; Mecklin and Järvinen, 
1986; Mecklin et al.,1986; Jass JR,1998) In tumour flow cytometry, the carcinoma cells 
appear to be more often diploid than the sporadic cancer cells (Kouri et al.,1990).  This 
may be one reason for a favourable prognosis. Some extracolonic organs can also be 
affected, especially the endometrium. Other organs, like the stomach, urinary tract, small 
bowel, ovary, and hepatobiliary tract may be affected as well (Watson and Lynch, 1993; 
Vasen et al., 1999). In these organs the malignancy usually develops at a later age 
(Aarnio et al., 1995). A high rate of microsatellite instability or replication errors (MSI+, 
MSI-H or RER) has been shown to be an important feature in the syndrome (Aaltonen et 
al., 1993; Ionov et al., 1993). Some patients may additionally have benign tumours, 
especially in the skin. When sebaceous adenomas and ceratoacanthomas are found 
together with an obvious inhereted form of CRC, the disease is called the Muir-Torre 
syndrome (Honchel et al., 1994). However, this syndrome seems to be part of the 
HNPCC spectrum, in which the MSH2 gene is mutated (Kruse et al., 1998). In the 
majority part of Turcot´s syndrome cases, malignant brain tumours, as well as CRC are 
included (Hamilton et al., 1995). Occasionally there are HNPCC patients with 
malignancies in other organs, as well, like the lung or breast. The reason for the wide 
tumour spectrum of HNPCC is propably genetic, but is as yet unclear.  
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6.2.4. Genetic background of HNPCC  
Hereditary non-polyposis colorectal cancer (HNPCC) is an autosomal dominant disorder, 
and the most common hereditary syndrome causing neoplasms in the gastrointestinal 
tract. In spite of the name of the syndrome, the tumours progress through adenoma-
carcinoma sequence and they are usually polypotic. But polyps are nevertheless not as 
frequent as in polyposis syndromes. In this sense they do not differ from sporadic ones. 
The first predisposing gene MSH2 was localized in 1993 in chromosome 2p16 and soon 
location was corrected to 2p21  (Aaltonen et al., 1993; Peltomäki et al., 1993; Fishel et al. 
1993). The second gene, MLH1, in chromosome 3p was mapped (Lindblom et al. 1993) 
and soon cloned as well (Papadoupolos et al., 1994; Bronner et al., 1994). Some time 
later the third gene, MSH6, important for HNPCC, was discovered (Miyaki et al., 1997; 
Berends et al., 2002). The gene is localized near MSH2 on chromosome 2p. Another two 
susceptible genes, PMS1 and PMS2 are associated with HNPCC (Nicolaides et al., 1994; 
Chadwick et al., 2000) but they seem to be of marginal importance in the disease. MLH3 
protein also plays a role in the mammalian mismatch repair mechanism (Lipkin et al., 
2000,2001). It seems, however, that MLH3 is not frequently involved in MSI-positive 
colorectal cancer as a hereditary or somatic component (Loukola et al., 2000; Hienonen 
et al., 2003).
6.2.5. HNPCC germline mutations 
The International Collaborative Group of Hereditary Colorectal Cancer (ICG-HNPCC) 
established in 1994 an international database (http://www.nfdht.nl) of mutations 
identified in families with Lynch (HNPCC) syndrome. In 2003, the ICG-HNPCC and the 
previous Leeds Castle Polyposis Group (PCPG) merged into a new group, INSIGHT 
(International Society of Gastrointestinal Hereditary Tumors). The present update (2003) 
of the database of the DNA mismatch repair gene mutations includes 448 mutations and 
occur in 748 families from different parts of the world (Tables 1 and 2; Peltomäki P and 
Vasen H, 2004). 
Table  1.    HNPCC associated human MMR genes 
_______________________________________________________        
Gene  Chromosomal location No. of exons 
_______________________________________________________   
MSH2   2p21   16 
MSH6   2p21   19 
MLH1   3p21-23  10 
PMS2   7p2   15 
MLH3   14q24.3  12
PMS1   2q31-33 Not determined 
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Table  2.    Number of mutations of considered pathogenic that have 
been deposited in the ICG-HNPCC/INSIGHT mutation database  
(http://www.nfdht.nl) as of July 31st, 2003 
_______________________________________________________        
Gene  Number of mutations  % 
_______________________________________________________   
MSH2   175   39    
MSH6     32     7 
MLH1   225   50 
PMS2       5     1 
MLH3     16     3
PMS1       1   <1 
Total   448   100 
As soon as the two major HNPCC genes, MSH2 and MLH1 were characterized, it 
became important to screen families for these mutations. In Finland, 55 HNPCC kindreds 
(35 of them fulfilled the Amsterdam criteria) were screened for mutations in these genes 
(Nyström-Lahti et al., 1996). It was shown that in more than half of all Finnish kindreds 
mutations were the Finnish MLH1 founder mutations (28 out of 55 kindreds) (Nyström-
Lahti et al., 1995, 1996). There are two Finnish MLH1 founder mutations (the mutations 
are not reported outside Finland). It was estimated that the age of the founder mutation 1 
is about 400-1075 years old. Mutation 2 is estimated to be yonger (125-55 years)(Moisio 
et al., 1996). In 2002 in 145 HNPCC families 94 mutations are identified in Finland 
(Järvinen H, personal communication). 
6.2.6.  HNPCC genes and mismatch repair mechanism (MMR) 
The DNA mismatch repair system was characterized in bacteria Escherichia coli. Single 
mispaired bases during DNA replication are recognized by protein complex 
MSH2/MSH6. Small insertions or deletions are recognized by the MSH2/MSH3 
complex, and mismatched bases are repaired by MLH1/PMS2 or MLH1/MLH3 
complexes (Table 3).  MSH4 and MSH5 are meiosis-specific proteins and do not 
participate in the repair of mismatched bases. The MLH1/MLH3 complex may also play 
a role in meiotic recombination. 
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Table 3.   The role of MMR proteins in DNA mismatch repair mechanism 
DNA rmismatch recognition:  Recognition of single base mispairs  
by MSH2/MSH6 complex 
      
Recognition of Insertion-deletion mismatches  
by MSH2/MSH3 complex 
DNA mismatch repair:  Repair by MLH1/PMS2 or/and 
    MLH1 / MLH3 complexes  
The functional role of MMR proteins (Boland et al., 2000) has been analysed and the 
crystal structure of MMR protein complexes have recently been constructed more 
precisely. Including the mismatch repair mechanism, MMR genes seem to have a more 
complex role in cell interactions, as in base excision repair (BER)(Bellacosa et al., 1999) 
and meiotic recombination The interaction between MMR and BER was shown by 
identifying MED1/MBD4 as an interactor with MLH1 as well as a link to DNA 
methylation (Bellacosa et al., 1999, 2001; Cortellino et al., 2003). BER acts on 
mismatches by mismatch-specific N-glycosylase. The E. coli mutY human homolog 
MYH gene acts as adenine glycosylases on A:C and A:G mismatches (al Tassan et 
al.,2002; Lipton et al., 2003). MMR proteins are also involved in the induction of 
apoptosis, and inactivation of MMR genes seems to inhibit cell death in HNPCC and 
sporadic malignant tumours as well (Hawn et al., 1995; Fischel et al., 1999; Nehme et al., 
1997). 
6.2.7. Microsatellite instability (MSI)  
Microsatellite instability is characterized by mutations, mainly deletions, in short repeat 
sequences (microsatellite repeats) of the genome. A high frequency of genomic instability 
(MSI-H) is observed in more than 80% of HNPCC carcinomas and in about 15% of 
sporadic colorectal cancers (Aaltonen et al., 1993; Thibodeau et al., 1998; Ionov et al., 
1993). It has been shown that sporadic MSI-H tumours differ from HNPCC tumours with 
microsatellite instability (Lothe at al., 1993; Peltomäki et al., 1993)   
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Table 3.   Recommendations for the evaluation of MSI.H and MSI-L 
The original National Cancer Institute microsatellite panel included microsatellite 
markers BAT26, BAT26, D2S123, D5S346 and D17S250; however, the following 
precautions may apply: 
1.  If only dinucleotide repeats are mutated, test a secondary panel of microsatellite               
     markers with mononucleotide repeats(e.g. BAT40 and/or MYCL) to exlude MSI-L 
2.  Dinucleotide repeats are less sensitive than mononucleotide repeats for MSI-H,     
     however, they provide an internal control for prevention of sample mix-up 
3.  A pentaplex panel of five quasimonomorphic mononucleotide repeats may be more  
     sensitive for MSI-H tumours than other microsatellite marker and may obviate the    
     need for normal tissue for comparison; this approach requires three or more mutant  
     alleles to indicate MSI-H 
For the definition of high frequency MSI (MSI-H) in the tumor sample, at least two of the 
five microsatellite markers should be positive, according to an internationally 
recommended reference panel (Table 3)(Rodriguez-Bigas et al., 1997; Boland et al., 
1998). When none of the markers is positive the tumour is designated as microsatellite-
stable (MSS). When only one of the markers is positive, the tumour is called 
microsatellite-low (MSI-L). These tumours with a lower frequency of instability have 
been shown to behave like MSS tumours (e.g. normal expression in MMR 
immunohistochemistry). Some of the markers, such as mononucleotide markers BAT26 
or TGF-β RII, have been found to be very specific for the MSI-H phenomenon. In some 
studies MSI-L tumours are considered as their own entity, and a connection is seen to the 
hyperplastic polyposis syndrome and to serrated adenomas (Jass JR, 2001; Mäkinen et 
al., 2001). As HNPCC tumours are nearly always microsatellite-instable (MSI-H), MSI 
analysis is the method of choice in their identification.  
There is discrepancy regarding the value of determining of the low level of microsatellite 
instability (MSI-L). Tumours with more than 30% MSI are designated as MSI-H (Boland 
et al., 1998; Dietmaier et al., 1997), but exact definition of a low level of MSI (MSI-L) is 
not determined. If the number of MSI markers had risen up to 377, MSI was observed in 
71 (79%) of 90 sporadic CRC cases. This means that a low level of MSI is observed in 
most colorectal cancers (Laiho et al., 2002). The result also shows that the sensitivity of 
the Bethesda panel markers is low in determining MSI-L tumours (Laiho et al., 2002). 
6.2.8.  Cancer risk and screening effect in HNPCC 
Aarnio et al. (1999) analyzed 360 MMR gene mutation carriers (MLH1 and MSH2 
mutations) for their risk of malignancy.  Standardized incidence ratios (SIR) were 
significantly increased for colorectal (68), endometrial (62), ovarian (13), gastric (6.9 ), 
biliary tract ( 9.1), uro-epithelial ( 7.6 ) and kidney (4.7) cancers. 
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At 70 years of age, the cumulative cancer incidence rates among mutation carriers were 
highest in patients with colorectal, endometrial, gastric and ovarian cancers, being 82, 60, 
13 and 12%, compared to the Finnish normal population, in which they were 1.6, 1.3, 0.8 
and 1.3%, respectively (Aarnio et al., 1999). 
Cancer patients with an MMR gene defect have a better survival rate than sporadic CRC 
patients due to possible aetiological factors mentioned earlier. The cumulative relative 
survival rate of HNPCC patients was 65% compared to 44% among patients with 
sporadic colorectal cancer (Sankila et al., 1996). The relatively good prognosis may be 
explained by the heavy mutation burden causing apoptosis of the malignant cell 
population, an immunological reaction in the tumour area (lymphoid reaction), or the 
diploidy chromosomal pattern of HNPCC malignant cells. It has been considered that 
MSI+ carcinomas could be more sensitive to chemotherapy than MSS carsinomas, but 
research results are not straightforward (de Vos tot Neederveen et al., 2004; Watanabe et 
al., 2004). 
The screening for CRC in HNPCC families has been shown to be beneficial. The cancer 
risk in a controlled 15-year trial of colonoscopy screening fell by over a half, and many 
CRC deaths were prevented, as the overall mortality decreased by 65% (Järvinen et al., 
1995, 2000).  Endometrial involvement should also be noticed in clinical practice. 
However, no advantage was gained by endoscopic screening of gastric cancer of 
mutation carriers (Renkonen-Sinisalo et al., 2002) 
6.2.9.  Histological features  
There are certain histological features in HNPCC tumours, though they are not of 
diagnostic importance for the disease (Mecklin et al.,1986; Shashidharan et al.,1999; 
Alexander et al.,2001). 
Poor differentation 
Colorectal carcinoma is graded into three categories according to regularity of cells and 
glandlike structures in the tumour: well differentiated (Grade I), moderately 
differenteated (Grade II) or poorly differentiated (Grade III) cancer. HNPCC tumours are 
more often poorly differentiated than sporadic ones (Mecklin et al., 1986; Shashidharan 
et al., 1999). Poor differentation means loss of glandlike structures. Invasive tumours 
grow also as solid islands or sheets of carcinoma cells. Malignant cells are often more 
pleomorphic than in Grade I or Grade II cancers. 
Mucinous pattern 
In the mucinous tumour pattern, the extracellular mucin accumulation is bounded by 
neoplastic epithelium. Colorectal carcinomas often consist of cancer foci with 
extracellular mucin production. A carcinoma is called mucinous if over 50% of the 
tumour area is composed of mucinous type of cancer (Hamilton and Aaltonen, 1999). 
Adenocarcinoma can also be partially mucinous (20% mucinous component)(Alexander 
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at al., 2001). In the carcinomas of MSH2 mutation carriers, the mucin production of 
mutation-positive individuals may be more prominent than in sporadic cases 
(Shashidharan et al., 1999). 
Medullary pattern 
A medullary carcinoma is a subtype of poorly differentiated adenocarcinoma. It consists 
of sheets and trabeculae of cancer cells with large nuclei and prominent nucleoli. Also a 
lymphoid reaction without a desmoid reaction is present (Ruschoff et al., 1997). This 
subtype possibly occurs mainly with MSH2 mutation (Shashidharan et al., 1999). 
Signet ring cell carcinoma 
Signet ring cell carcinoma is a variant of adenocarcinoma in which over 50% of the 
tumour cells contain prominent intracytoplastic mucin (Sasaki et al., 1998). The name 
comes from the distinct form of the cancer cells. Intracellular mucin presses the nucleus 
against the cell membrane, and malignant cells invade normal tissue as small cell groups 
or single cells. 
Host immune reaction 
Host immune reaction is usually present in medullary type of cancer. Crohn´s-like 
lymphoid reaction, intratumoral lymphoid reaction and intraepithelial lymphocytosis  are 
often present in HNPCC carcinomas. Tumour-infiltrating lymphocytes (TIL) often 
surround the mucinous component of the cancer. TIL are mostly CD3-positive T-cells  
and seem to be over-represented in MSI-H cancers; they may be present in subjects with 
MLH1 mutation (Dolcetti et al., 1999). A host immune reaction may be one reason for 
the relatively good prognosis of HNPCC cancer (Kim et al., 1994).  
Residual adenomas adjacent to the carcinoma are common in HNPCC as well as in 
sporadic cancer. Residual adenomas with a high level of microsatellite instability (MSI+) 
seem to be villous adenomas more often than in the case of residual sporadic adenomas 
(Jass JR 1995; Iino et al., 2000). Sporadic MSI-H adenomas often display a special 
serrated pattern, and over 40% of these residual adenomas are villous (Mäkinen et al., 
2001; Jass JR,  2001). 
The above microscopic observations have been confirmed only partly (Jass JR, 2002). 
Poor differentiation, medullary type of carcinoma and host immune response seem to 
remain the most reliable morphological features in diagnostic microscopy, although 
histopathological evaluation has poor sensitivity in determining a suspected HNPCC 
subject. These findings can nevertheless be diagnostically helpful when combined with 
other information about the patient, such as family history. Nevertheless, in stomach 
cancers of young HNPCC patients, intestinal type of cancer has been shown to be 
distinctively more common than diffuse type of cancer. In contrast, among young 
sporadic cancer patients mucocellular, diffuse type of cancer is more common (Aarnio et 
al., 1997).  
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6.2.10. Immunohistochemistry of MMR gene products 
Commercially produced monoclonal antibodies against MLH1 and MSH2 proteins have 
been available since 1994. And immunohistochemistry (IHC) of MLH1 and MSH2 
proteins for diagnostic purposes has been evaluated parallelly with microsatellite studies 
(Dietmaier et al., 1997; Thibodeau et al., 1998; Kim et al., 1998; Debniak et al., 2000) 
Some of the available antibodies have been used successfully for the recognition of 
MMR gene products. Nearly all MSI-H tumours have displayed loss of MMR protein 
expression with either MLH1 or MSH2 monoclonal antibody (Dietmaier et al., 1997; 
Thibodeau et al., 1998; Kim et al., 1998). Especially monoclonal antibodies against 
MSH2 proteins have been found to work well.
Some difficulties have nevertheless been reported especially with MLH1 antibodies. It 
was therefore necessary to test the accuracy of the immunohistochemistry. An 
international Collaborative Group of HNPCC (ICG-HNPCC) has been coordinating the 
development of the diagnostic methods of HNPCC. The group drew up the Amsterdam 
criteria for the identification of HNPCC patients (Table 4.), and is also interested in new 
methods like the IHC in order to find  the best available diagnostic tools for daily clinical 
practice.
6.2.11.  Diagnosis of HNPCC  
The international collaborative group of HNPCC determined diagnostic criteria for the 
disease in 1991, i.e. Amsterdam criteria I (Table 4; Vasen et al. and ICG-HNPCC, 1991). 
The criteria were based on anamnestic information, and have been criticized because 
extracolonic lesions or families with low penetrance were excluded.  In clinical practice, 
a sufficiently detailed family history fulfilling the criteria is often not available. The 
revised version of the criteria was established in 1999 (the Amsterdam criteria II, Vasen 
et al. 1999; Park et al. 2002). This version included extracolonic lesions. The first criteria 
have been changed as follows: at least 3 relatives should be affected with an HNPCC-
accociated cancer (CRC, cancer of the endometrium, small bowel, ureter or renal pelvis). 
Other cancer sites were not added to the list eventhough other organs might be affected. 
In addition the tumours should be verified by histological examination. 
Table 4.   Amsterdam criteria I    
There should be at least 3 relatives with CRC, and the following criteria should be    
fulfilled: 
1.  One patient has to be a first-degree relative of the other two 
2.  At least two consecutive generations must be affected 
3.  At least 1 CRC should be diagnosed before the age of 50 
4.  Polyposis syndromes (especially familial adenomatous polyposis, FAP) must be   
     excluded 
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In 1997 the National Cancer Institute (USA) sponsored an international workshop which 
made a recommendation for a reference panel of five microsatellite markers to determine 
microsatellite instability (MSI) in tumours (Table 3; Boland et al., 1998). Tumours would 
be characterized high-frequency MSI (MSI-H) if two or more markers show instability, 
and low-frequency MSI (MSI-L), if only one of five markers shows instability.  The 
National Cancer Institute determined also " the Bethesda guidelines" (Table 5.) to assist 
in the selection of tumours for microsatellite analysis (Rodriguez-Bigas et al., 1997). The 
guidelines were updated in 2004 as the Revised Bethesda Guidelines for HNPCC (Table  
6; Umar et al., 2004), as well as new recommendations for the evaluation of 
microsatellite instability (Table  3; Umar et al., 2004), 
Table 5 . Bethesda Guidelines for testing of colorectal tumours for microsatellite 
instability 
1.  Individuals with cancer in families that meet the Amsterdam Criteria 
2.  Individuals with two HNPCC-related cancers, including synchronous metachronous  
     colorectal cancers or associated extracolonic cancers. 
3.  Individuals with colorectal cancer and first-degree relative with colorectal cancer  
     and/or HNPCC-related extracolonic cancer and/or a colorectal adenoma; one of the 
     cancers diagnosed at age < 45y, and the adenoma diagnosed at age < 45y  
4.  Individuals with colorectal or endometrial cancer diagnosed at age < 45y 
5.  Individuals with right-sided colorectal cancer with undifferentiated  
     pattern(solid/cribriform) on histopathology diagnosed at age < 45y  
6.  Individuals with signet-ring-cell-type colorectal cancer diagnosed at age < 45y 
7.  Individuals with adenomas diagnosed at age < 45y      
Table 6. The Revised Bethesda Guidelines for testing of colorectal tumours for 
microsatellite instability 
Tumours from individuals should be tested for MSI in the following situations: 
1.  Colorectal cancer diagnosed in a patient who is < 50y 
2.  Presence of synchronous, metachronous colorectal or other HNPCC-associated 
      tumours, regardless of age 
3.  Colorectal cancer with the MSI-H histology diagnosed in a patient who is < 50y 
4.  Colorectal cancer diagnosed in one or more first-degree relatives with an HNPCC- 
     related tumor, with one of the cancers being diagnosed < 50y 
5.  Colorectal cancer diagnosed in two or more first-degree or second-degree related  
     tumours, regardless of age 
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Information for the diagnosis should be collected from family history, clinical and  
histological features of the disease, MSI analysis and finally, genetic analysis (Loukola et 
al., 1999; Lynch, de la Chapelle, 2003). For clinical purposes, MSI-analysis and  
immunohistochemistry have been included in the diagnostic criteria (de la Chapelle, 
2002; Umar et al., 2004). 
7. USE OF MICROSATELLITE MUTATIONS AS MOLECULAR CLOCK 
Human population genetic studies have shown that older populations have greater genetic 
diversity than younger ones (Ayub et al. 2003).  The age of a population can be estimated 
according to changes in repeated DNA sequences of the genome, presuming that the 
mutation rate is constant.  
The simplest model for colorectal tumour progression is a ladder model (Nowell, 1976), 
where certain phenotypic alterations follow each other.  The adenoma-carcinoma 
sequence is a model for multistep colorectal cancer progression (Kinzler and Vogelstein, 
1996). Since its invention it has become a widely accepted model for carcinogenesis in 
the gastrointestinal tract.  
When cell division occurs in homeostatic tissue, one daughter cell survives and the other 
supposedly dies. The vast number of cell divisions compared with the actual size of the 
adenoma or carcinoma suggests that over 90 % of the colon cancer cells die (Steel GG, 
1967). Tumour cells may remain dormant as well. Dormancy can follow reduced mitotic 
activity or be a balance between mitosis and death (Wheelock, 1981; Holmgren et al., 
1995). The mutation rates in most tumours are low, less than one mutation per 100,000 
divisions. This makes it difficult to observe mutation rates, as only a few divisions occur 
in microsatellite-stable (MSS) tumours even if the cells divide daily. The age of a tumour 
is the time between initiation and clinical presentation. 
In mutator phenotype tumours (MSI-H), the mutation rate can be elevated up to100 -fold 
because the tumours lack mismatch repair function. In HNPCC tumours, the inability to 
repair DNA mismatches accelerates the accumulation of genetic mutations,  and MS 
mutations occur frequently enough to document tumorigenesis  ( Shibata et al.,1994; 
Tsao et al., 1999; 2000). Comparison of allelic differences in tumour patterns provides 
information about the age of the tumour.  
8. POLY-A DELETIONS IN HNPCC 
HNPCC tumours are strongly linked with high microsatellite instability (Aaltonen et al., 
1993; Thibodeau et al., 1993; Ionov et al., 1993). Altered MS loci have been useful for 
the classification of microsatellite instability (MSI). It has been considered that some MS 
mutations may even precede visible change in tumour morphology or before a 
"gatekeeper" mutation (Parsons et al., 1995), and gradual accumulation of noncoding MS 
mutations may occur without changes in phenotype (Ionov et al., 1993; Zhou et al., 1997; 
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Percecepe et al., 2000). PolyA simple repeat sequence mutations are common in tumours 
with MSI-H (Ionov et al.1993; Boland et al., 1998). PolyA repeats are sensitive indicators 
of microsatellite instability, as most of the mutations are deletions (Percesepe et al., 
2000). The counting of polyA mutations may be simpler than stepvise mutations in 
dinucleotide repeat loci (Tsao et al., 2000). Deletions occur stepwise with loss of a single 
or a few bases at a time (Shibata et al., 1994; Percesepe et al.,2000; Tran et al., 1997 ). 
Therefore PolyA deletions not only indicate loss of DNA mismatch repair, but also 
provide information on the time of occurrence of MMR gene mutation (Shibata et al., 
1994; Blake et al., 2001). 
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AIMS OF THE STUDY 
1. To determine the frequency of MLH1 and MSH2-associated hereditary 
nonpolyposis colorectal cancer. 
2. To evaluate screening methods for hereditary nonpolyposis colorectal cancer. 
3. To evaluate the role of DPC4/SMAD4 gene in colorectal tumour progression. 
4. To evaluate the tempo of tumour growth by analyzing the diversity of 
microsatellites in HNPCC tumours. 
5. To evaluate the moment of loss of the mismatch repair (MMR) function in 
carcinogenesis.  
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MATERIAL AND METHODS 
1. COLORECTAL CANCER PATIENTS AND TUMOUR SAMPLES (I, II) 
n order to evaluate the incidence of HNPCC  (509 colorectal carcinoma samples) and to 
evaluate the screening methods for HNPCC (another 535 carcinoma samples), fresh 
frozen tumour samples were collected in the surgical departments of nine large regional 
hospitals in eastern and southern Finland (Second Department of Surgery, Helsinki 
University Central Hospital; Departments of Surgery of the Central Hospitals of Joensuu, 
Mikkeli, Lappeenranta, Kajaani, Kotka, Savonlinna and Jyväskylä; Departments of 
Surgery and Internal Medicine, Kuopio University Hospital). The samples were collected 
in 1994 -1998. In the two-phase study there were altogether 1044 colorectal carcinoma 
samples available (509 from Study I and 535 from Study II). Tumour specimens with 
normal tissue controls were sent to the Department of Medical Genetics, University of 
Helsinki, as fresh frozen samples, and they were examined histologically at the 
Department of Pathology, University of Helsinki. Frozen tissue sections were stained 
with Toluidine blue before cutting the tissue and at the end of tissue removal, so that the 
sections used for DNA extraction would have as many tumour cells as possible. Only 
tumours with over 50% carcinomatous tissue were accepted to the study. The histology of 
the frozen sections was compared to the original pathological/anatomical diagnosis of 
each tumour.  The patients family history was documented by identifying all first-degree 
relatives in the official population registries, and verifying the relatives` cancer diagnosis 
from the Finnish Cancer Registry. The data on previous cancers of the patients were also 
obtained from the Cancer Registry. 
2. MICROSATELLITE ANALYSIS (I, II) 
In the study I including 509 tumours, 236 carcinomas of the series, analysis for 
microsatellite instability (MSI) was performed with radio-active-labeling techniques, 
whereas the last 273 carcinomas were analyzed by fluorescence-based PCR methods. The 
presence or absence of microsatellite instability was determined by a reviewer with no 
prior knowledge of the clinical features of the patients. With the radioactive technique the 
236 pairs of tumour and normal DNA samples were first analyzed with a set of seven 
microsatellite markers (D5S404, D17S787, D5S346, D1S216, D11S904, D10S197, and 
TP53).  With fluorescent labeling and subsequent fragment analysis by an automated 
sequencer, all 273 pairs of tumor and normal DNA samples were directly analyzed with 
16 markers (D8S254, MYC, NM23, D5S346, TP53, D1S228, D8S261, D7S496, 
D8S137, DCC, D7S501, MCC, D5S318, D1S507, D119S394, and RB1). In the order to 
verify uniformly the microsatellite status of the patients, the whole series of 509 tumours 
was analyzed by a PCR-based method, using radioactively labeled BAT26, a 
mononucleotide marker sensitive to microsatellite instability.  
In the Study II DNA was extracted from  535 colorectal carcinoma specimens and  was 
studied for Microsatellite instability by using mononucleotide (poly-A)markers BAT26 
and TGFβRII by fluorescence-based polymerase chain reaction (PCR). Microsatellite 
markers wereamplified from the tumour DNA utilizing fluosescently labeled primers. 
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PCR products wereloaded on 6% polyacrylamide gels and run on an ABI PRISM 377 
DNA Seguencer(Perkin Elmer Applied Biosystems, Foster City, CA, USA). The data 
were collected automatically and analyzed by GeneScan 3.1 software (Perkin Elmer). 
The results were evaluated visually by two reviewers. All tumors showing aberrant 
patterns were re-analyzed with the matching normal DNA to confirm the somatic origin 
of the aberrant alleles. Patients whose tumors showed alleles that were not present in the 
corresponding normal DNA were acknowledged as MSI-H. 
3. MUTATION ANALYSIS (I, II) 
In Study I the first 198 patients whose tumors had microsatellite instability, were 
investigated for germ-line mutations in MLH1 and MSH2 by two dimensional denaturing 
gradient gel electrophoresis (Wu et al., 1997). For the 311 subsequent patients, tumours 
with microsatellite instability were analyzed for mutations by direct sequencing.  The 
promoter regions and each exon of the MLH1 and MSH genes from genomic DNA were 
individually amplified in a Perkin Elmer cycler, and sequenced directly with 
fluorescence-labeled M13 forward and reverse primers. Samples of normal tissue from 
509 patients were analyzed with a PCR based method regardless of MSI status for a 
common founder mutation, referred to as mutation 1, that cannot be detected by the 
analytic approaches. 
In Study II 535 patients were scrutinized for two most common mismatch repair gene 
mutations in Finland. Mutation 1 was detected by the PCR -based method and mutation 2 
was detected by allele-specific oligonucleotide hybridization (Nyström-Lahti et al., 
1995). If neither of the founder mutations were detected but the patient´s tumour had 
displayed MSI, mutation analysis of MLH1 and MSH2 was performed by direct genomic 
sequencing of the coding exons, including the flanking intronic regions and promoter 
regions. For detecting of mutation 1, three primers were used in a single amplification 
reaction. Primers 1 and 2 amplify a fragment of 634 bp specific for the mutated allele. 
Primers 2 and 3 amplify a 475 bp fragment specific for the normal allele. Mutation 2 was 
analyzed by allele specific oligonucleotide hybridization (Nyström-Lahti et al., 1995).  
If neither of the founder mutations were found in MSIH samples, a thorough MLH1 and 
MSH2 mutation analysis was performed by direct genomic sequencing. Each exon as 
well as the promoter region was amplified separately utilizing PCR amplification kits 
containing primers, nucleotides, and buffer (Perkin Elmer commercial kit), and 
AmpliTaqCOLD polymerase (Perkin Elmer). Direct sequencing was performed utilizing 
the ABI PRISM Dye Terminator or ABI PRISM dRhodamine cycle sequencing kits 
(Perkin Elmer). Sequencing products were electrophoresed on 6% Long Ranger gels 
(FMC BioProducts) and analyzed on an Applied Biosystems model or 377DNA 
sequencer (Prerkin Elmer). 
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4. IMMUNOHISTOCHEMISTRY (III, IV) 
4.1.  Immunohistochemical labelling for MLH1, MSH2 (IIIA) 
For the international study a series of 20 colorectal cancer specimens were collected from 
different international Institutions by the coordinators. The specimens including tumours 
with known presence or absence of MSI and DNA mismatch repair enzyme (MLH1, 
MSH) mutation. Unstained slides from each tumour were sent to 18 centers for MLH1 
and MSH2 immunohistochemistry. Each center used its own staining protocol and own 
antibody dilution, but analyzed the slides and scored the staining results according to the 
recommended scoring system.  The recommended scoring system (1=1-10% of tumour 
cells positive, 2=11-50%, 3=51-80%, 4=>80%) considers the result positive if any 
tumour cells display positive nuclear staining with the antibody. Each center returned the 
stained slides, their interpretation of the results and their staining protocols to a central 
representative (GM). 
As a only representative from Finland, the Department of Pathology, Haartman Institute 
(Department of Laboratory Diagnostics, Helsinki University Hospital) used following 
monoclonal antibodies:  MLH1 (Pharmingen, clone G 168-728) and MSH2 (Calbiochem; 
Oncogene Sciences, clone FE-11, cat. NA27).  
The tissue sections were mounted on slides coated with 3-aminopropyl-triethoxy-silane 
(Sigma, St.Louis, Mo, USA) and dried at 37°C. The sections were deparaffinized in 
xylene, rehydrated through a graded alcohol series to distilled water. The samples were 
then microwaved at high power 4 x 5 min in citrate buffer, then cooled and washed in 
phosphate-buffered saline (PBS). Avidin-biotin-complex immunoperoxidase technique 
was performed by using a Techmate Automatic machine with a commercial Elite ABC 
kit(Vectastain, Vector Laboratories, Burlingame, CA, USA). Endogenous peroxidase was 
blocked by incubating in hydrogen peroxide with methanol, then incubated with non-
immune horse serum. The primary antibody was incubated for one hour. The sections 
were then incubated in biotinylated second antibody and the peroxidase-labelled avidin-
biotin complex for 30 min. All dilutions were made in PBS (pH 7.2) and the incubation 
was done in humid chambers at room temperature. The staining was visualized with DAB 
solution for 15 min at room temperature. The sections were counterstained 20s in 
Mayer´s hematoxylin, rinsed in water and mounted in aqueous mounting media 
(Aquamount, BDH, Poole, UK). 
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4.2.  Immunohistochemical labelling for MLH1, MSH2 and MSH6 - Comparison of 
MSI analysis and IHC (IIIB) 
MMR-protein immunohistochemistry was available for routine diagnostic practice since 
september 2000 at the Department of Pathology, Haartman Institute (Department of 
Laboratory Diagnostics, Helsinki University Hospital. Altogether 174 HNPCC-suspected 
tumour samples were sent to the Department of Pathology, Haartman Institute 
(Department of Laboratory Diagnostics, Helsinki University Hospital) for diagnostic 
purpose. Tumour samples were collected from the departments of pathology of different 
hospitals in Finland, according to requests of clinicians or genetic counselors. The 
samples were collected in the period between September 2000 and December 2003. 
Diagnostic IHC was evaluated together with histopathological evaluation of tumour 
specimens (HE staining) and tissue was removed from the paraffin block specimens for 
microsatellite analysis. The MSI analyses were done at the Department of Medical 
Genetics, Haartman Institute (Department of Laboratory Diagnostics, Helsinki University 
Hospital).
The following two monoclonal antibodies were used for IHC, as recommended by ICG-
HNPCC (International Collaborative Group of HNPCC) in study III: 
MLH1 (Pharmingen, clone G 168-15, cat. 13271 A), MSH2 (Calbiochem; Oncogene 
Sciences) clone FE-11, cat. NA27). Additionally MSH6 / GTBP ( Transduction Lab, cat.-
No. G70220) was included to diagnostic antibody panel. 
Microscopic evaluation was based on the ICG-HNPCC recommended scoring system: 
(1=1-10% of tumour cells positive, 2=11-50%, 3=51-80%, 4=>80%) considers the result 
positive if any tumour cells display positive nuclear staining with the antibody. 
4.3. Immunohistochemical labelling for SMAD4 (IV) 
SMAD4 monoclonal antibody raised against a peptide corresponding to aminoacids 1-
552 representing full-length SMAD4 of human origin (Smad4 B-8; sc-7966, Santa Cruz 
Biotechnology Inc., Santa Cruz, CA) was used for SMAD4 protein expression. 
Immunohistochemistry was used to analyze the presence of SMAD4 protein from 80 
paraffin-embedded specimens. For the evaluation of the involvement of SMAD4 gene in 
sporadic colorectal neoplasia, 53 unselected and 27 MSI-H colorectal carcinoma samples 
were collected. For SMAD4 immunohistochemical labelling, 53 surgical, paraffin-
embedded resection specimens, of unselected colorectal carcinoma were collected. In 
addition, a series of 27 archival colorectal cancer samples displaying microsatellite 
instability (MSI) or mutator phenotype, were available for the study. The 80 tissue 
samples were originally fixed in 10% neutral buffered formalin and paraffin-embedded. 
Hematoxylin-eosin staining was performed. The tumourswere evaluated by two 
pathologists. All 80 samples contained areas of normal colonic mucosa adjacent to the 
carcinoma; these served as normal epithelium controls. Unstained 4µm tissue sections 
were mounted on slides coated with 3-aminotpropyl-triethoxy-silane (Sigma, St. Louis, 
MO, USA). The sections were deparaffinized in xylene, and rehydrated through a graded 
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alcohol series to distilled water. After deparaffinization, the sections were pretreated in a 
microwave oven in buffered sodium citrate. For immunohistochemical analysis, the 
avidin-biotin complex immunoperoxidase technique was applied using the commercial 
Elite ABC kit (Vectastain, Vector Laboratories, Burlingame, CA, USA). The slides were 
labeled with a 1:2000 dilution of the primary antibody and incubated overnight. The 
sections were then incubated in biotinylated second antibody and peroxidase labeled 
avidin-biotin complex for 30 min. All dilutions were made using PBS (pH 7.2). The 
incubations were carried out in humid chambers at room temperature. Staining was 
visualized using 3-amino-9-ethylcarbazole (Sigma, St. Louis, MO, USA) solution for 15 
min at room temperature, and the sections were counter-stained 20s in Mayer´s 
hematoxylin, rinsed in water and mounted in aqueous mounting media. 
5. SMAD4 GENE IN COLORECTAL CARCINOMA SAMPLES (IV) 
5.1. LOH analysis of 18q21 region (SMAD4)
Loss of heterozygosity (LOH) analysis on the 28 unselectedcolorectal carcinoma and 
normal tissue sample pairs was performed using two fluorescent labelled microsatellite 
markers (18S1156 and D18S363).  PCR reactions were carried out in a 20 µl reaction 
volume containing 100ng genomic DNA, 1xPCR buffer (Applied Biosystems, Foster 
City, CA, USA), 250 µM of each dNTP (Finnzymes, Espoo, Finland), 0,5 µM of each 
primer, and 2 units of AmpliTaqGOLD polymerase (Applied Biosystems). MgCL2
consentrating was 2 mM. The following PCR cycles were used for amplification: 10 min 
at 95°C, 30 cycles of 45 s at 95°C 45s at 54°C, and one min at 75°C. Final extension was 
10 min at 7°C. PCR products were loaded onto  6% polyacrylamide gels and run on an 
ABI PRISM 377DNA Sequencer (Applied Biosystems). The data were collected 
automatically and analysed by GenScan 3.1.software (Applied systems). LOH was scored 
by calculating the ratio of peak areas of constitutional alleles. If L<0.6 or L>1.67, one of 
the tumour alleles had decreased by more than 40%, implicating LOH. 
5.1. TGF-βIIR mutation analysis 
The polyA tract in the coding region of transforming growth factor type II receptor gene 
was scrutinised for deletions by PCR amplification using fluorescent-labelled primers and 
subsequent fragment analysis by automated sequencer. There were 25 MSI tumours 
available for the analysis. The PCR reactions were carried out in a 10 µl reaction volume 
including 100ng genomic DNA, 1xPCR reaction buffer( PE/ABI), 200 µM of each dNTP 
(Finnzymes), 0,3 µM of each primer, and 1.5 units of AmpliTaqGOLD polymerase 
(PE/ABI). MgCL2 concentration was 1,5mM. The following PCR cycles of 30 s at 94°C, 
75 s at 55°C, and 30 s at 72°C. Final extension was 10 min at 72°C. The forward (F) and 
reverse (R) primers were: 5´ -CTTTATTCTGGAAGATGCTG; R: 5´-
GAAGAAAGTCTCACCAGGC. 
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6. ESTIMATING THE TUMOUR AGE FROM XENOGRAFT SECTIONS AND 
HNPCC SAMPLES (V) 
Sections from six human xenografts grown in mice and 16 human colorectal tumours 
from HNPCC patients carrying hMLH1 mutations. were available for evaluating the 
tempo of tumour growth. In order to obtain the xenografts, single cell clones of the 
hMLH1-deficient mutator colon cancer cell line HCT 116 were isolated and grown in 
culture. HCT 116 cells were subcutaneously injected into nude mice (BALB/c nu/nu). 
The xenocrafts were fixed in formalin and paraffin embedded. Six xenografts ranging in 
age from 49 to 89 days (including 20 days in culture) were analyzed. DNA was extracted 
from different topographic cell populations of human mutator phenotype tumours (200-
400 cells) also from 16 HNPCC paraffin-embedded tumour specimens (adenomas, 
primary cancer specimens and metastatic tumours). Standard histologic sections of the 
xenografts and HNPCC tumours from patients with germline hMLH1 mutations were 
placed on plastic slides and stained. The cell samples were microdissected from the 
plastic slides for DNA extraction and microsatellite analysis. For microdissection of the 
tumour samples, the SURF (selective ultravioletradiological fractionation)  (Shibata D, 
1994) method was used. Microsatellite PCR was done by dinucleotide CA–repeat MSs 
from noncoding genomic regions (Mfd 27, Mfd41, Mfd47, Mfd 57). The size of each MS 
allele was estimated based on the largest strong ladder band, and compared to normal 
tissue germline alleles.  
MS alleles were studied from different parts of the tumours, and the number of cell 
divisions was estimated from the observed MS diversity. A mathematical model was 
derived assuming constant mutation rate, stepwise mutation, and constant cell division 
with loss of one of the two daughter cells. Insertions and deletions are assumed equally 
likely. Tumour age was measured as the number of divisions estimated necessary to 
generate the observed MS diversity. The number of divisions is inversely proportional to 
the mutation rate. In relatively stable tumours, homogeneous tumour cells divide at equal 
rates after an initial clonal expansion. One daughter cell survives after a cell division. In 
such “ stable” tumours, large numbers of cell divisions are balanced by cell death leading 
to diversity of alleles. In rapidly growing tumours, on the other hand, cell division 
exceeds cell death and less MS diversity is seen in the tumour cells. 
7. EVALUATION OF POLY-A DELETIONS IN HNPCC (VI) 
For the evaluation of poly-A deletions in HNPCC, six paraffin-embedded adenoma 
samples and ten carcinoma specimens from 11 Finnish HNPCC patients were examined.  
Clinical information was available. Surveillance intervals are defined as the time between 
a negative clinical examination (colonoscopy or prior surgery) and removal of a new 
tumour. Normal DNA was free of tumour and tumour regions were microdissected to 
obtain greater than 60% of tumour cells. Germline MLH1 or MSH2 mutations were 
confirmed by sequencing. The t -test was used to determine the significance between 
means. PolyA deletions were measured by comparing germline and tumour sizes. Four 
polyArepeat loci were examined (BAT20, BAT25, BAT26, and BAT40). Length of 
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mononucleotide repeats were estimated by comparing the most intense polymerase chain 
reaction (PCR) product band between tumour and normal DNA after electroforesis on 6% 
sequencing gels, incorporating [33P]-dCTP (NEN Research Products, Boston, MA) with 
35 to 38 PCR cycles. In some cases, to better distinguish between tumour and 
contaminating normal alleles, tumour DNA was diluted  before PCR to avoid overlapping 
stutter bands. 
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RESULTS 
1. INCIDENCE AND EVALUATION OF SCREENING STRATEGIES FOR 
HEREDITARY COLORECTAL CANCER (Studies I and II) 
Colorectal cancer specimens were prospectively collected from 1044 unselected newly 
diagnosed patients and screened for microsatellite instability utilizing microsatellite 
marker BAT26. Patients with MSI-H tumours were screened for MLH1 and MSH2 
mutations by genomic sequencing. In addition, all 1044 patients were studied for two 
relatively frequent founder mutations (MLH1 mutations mut1 and mut 2) in Finland. 129 
(12%) of these patients had an MSI-H colorectal cancer. 28 (2.7%) of them had a 
germline mutation, 26 in MLH1 and two in MSH2. Thus the incidence of MLH1 and 
MSH2 associated HNPCC was 2.7%.  
Three main high-risk criteria for identification of HNPCC patients among the unselected 
colorectal cancer patients were evaluated:   1) age under 50,   2) a previous or 
synchronous colorectal or endometrial cancer or   3) one first-degree relative with 
colorectal or endometrial cancer. One or more of these criteria were fulfilled in 239/1044 
patients (23%). Of these 239 patients 54 had MSI(+) tumours (5% of total). All but one 
(27/28) of the mutation-positive patients were among these 54 patients.  This allowed us 
to propose a scenario for HNPCC diagnosis in which only high-risk patients (23%) are 
studied for MSI, and only those with MSI-H tumours (5%) were subjected to mutational 
analysis. Our data suggest that in this way 96% of all patients positive for a germline 
mutation in MLH1 and MSH2 will be detected. 
2. IMMUNOHISTOCHEMISTRY OF MMR GENE PRODUCTS (Study III) 
2.1. Immunohistochemical labelling for MLH1 and MSH2 
Results of an international collaborative study (Study IIIA) 
Immunohistochemical slides stained for MLH1 and MSH2 and evaluation protocols were 
collected from 18 of the participating international histopathological centres. Slides from 
16 centres were approved for the final staining evaluation.  
hMSH2  
Ten centres reported 84-100% sensitivity identifying loss of protein hMSH2 expression 
in all six of the six appropriate cases samples with known mutation and loss of 
expression. 14 of 16 the centres showed 100 % specificity in their original interpretation 
of the slides. With two exceptions, all laboratories showed good discriminatory value 
between the positive and negative cases. Re-review of the returned slides indicated lack 
of internal positive control (no MMR protein expression in normal tissue) in two of 6 
MSH2-negative cases in 8 of the 16 centres. The other eight centers had 100% sensitivity 
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and 93% (n=1) to 100% (n=7) specificity on re-review. The reason for the lack of internal 
positive control could be the variation in fixation or processing among the cases. 
hMLH1 
Four laboratories performed MLH1 staining protocols with highly discriminatory 
staining. Other laboratories performed less reliable staining results. The variation in 
staining quality was much greater for MLH1  than for MSH2. The centres reported 0-
100% sensitivity, with 5 of the 16 laboratories identifying 9 to 11 out of 11 cases with an 
MLH1 mutation. 
On original review by each center, the specificity was 40–100%. Re-review of the 
returned slides  resulted in sensitivities of 0-90%, with slides from four laboratories 
appropriately detecting 9-10 out of 11 MLH1-negative cases. These four laboratories had 
specificities of 90 (n=1) to 100% (n=3). The other 12 centres had difficulties because of 
the lack of internal positive control or high backround staining.
There was a great variaty in staining results. Especially with MLH1 antibodies, IHC 
showed poor sensitivity and specificity. Therefore, according to the result from four 
laboratories with specificity of 90 to 100%, the following two monoclonal antibodies 
were highly recommended by ICG-HNPCC (International Collaborative Group of 
HNPCC): 
MLH1 (Pharmingen, clone G 168-15, cat. 13271 A), MSH2 (Calbiochem; Oncogene 
Sciences) clone FE-11, cat. NA27). 
2.2. Immunohistochemical labelling for MLH1, MSH2 and MSH6 and its relationship 
with MSI (IIIB). The results of diagnostic samples at Haartman Institute, 
Department of Pathology, University of Helsinki (data not previously published) 
Altogether 174 tumour samples were stained for MLH1, MSH2 and MSH6 
immunohistochemistry at the Department of Pathology, Haartman Institute (Department 
of Laboratory Diagnostics, Helsinki University Hospital). MSI analysis was performed at 
the Department of Medical Genetics Haartman Institute (Department of Laboratory 
Diagnostics, Helsinki University Hospital). All the cases were suspected for HNPCC. 
Loss of expression for at least one of the three antibodies was observed in 35 cases (Table 
7). All the tumours displaying loss of MMR-protein expression (Figure 3) were colorectal 
carcinomas (Table 7). Loss of hMLH1 expression was observed in 22 tumours. In ten 
cases loss of protein hMSH2 was seen (in two cases the result was not reliable). Three 
tumours showed loss of expression by MSH6 antibody. In all of the ten MSH2 cases 
there was also loss of expression in MSH6 staining, as is often the case in patients with 
MSH2 mutation (Schweizer et al., 2001). In contrast, in the MSH6 mutation cases, only 
hMSH6 expression is lacking. 32 out of 35 carcinomas displaying loss of protein 
expression showed high microsatellite instability (MSI-H). In three cases showing normal 
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result in MSI-analysis (one MLH1 and two MSH2 cases), the analysis was not reliable 
because of the low percentage (under 25%) of cancer cells in thetumours  
Table 7. The result of MSI-analysis of 35 cancers displaying loss of expression of  
MMR -proteins (# = not a reliable result). 
Loss  of expression Microsatellite analysis Total 
          
   MSI - MSI +     
           
MLH1   # 1  21    22  
MSH2   # 2  8    10  
MSH6     3    3  
           
Total   # 3  32    35  
139 out of 174 tumours displayed normal MMR-protein expression (Table 8). Most of the 
cases proved to be colorectal tumours (adenomas and carcinomas), but there were 
tumours from other organs as well. None of those extracolonic tumours showed loss of 
MMR-protein expression. Two of the colorectal cancers were MSI-positive. In 9 cases, 
microsatellite analysis was not available because of the low tumour cell percentage 
(under 25%) or the analyses were not succesful for other reasons. 
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Table 8. The result of MSI-analysis of 139 tumours displaying normal MMR  
  protein expression. 
Tumour location  Microsatellite analysis Total 
          
   MSI - MSI + No result 
           
Colon and rectum   114  2  7  123  
Ileum   2      2  
Stomach   1    1  2  
Omental metastasis  1      1  
Liver metastasis  1    1  2  
Soft tissue metastasis 
(peritoneum) 
 1      1  
Lymh node metastasis  1      1  
Breast   2      2  
Endometrium   1      1  
Fallopian tube   3      3  
Ovary   1      1  
           
Total   128  2  9  139  
Figure 3. Immunohistochemical labelling of a HNPCC tumour with loss of MLH1 
expression. In each picture, carcinoma is on the left and normal colonic mucosa on the 
right. 
Left: Loss of MLH1 expression in the nuclei of carcinoma cells.   
Middle: Normal MSH2 expression.  Right: Normal MSH6 expression. 
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3. LOSS OF SMAD4/DPC4 PROTEIN AND EVALUATION OF CHROMOSOME 
18q LOH (IV) 
3.1. SMAD4 expression on colorectal carcinomas  
For the evaluation of SMAD4 immunohistochemical staining 80 colorectal cancer 
specimens were available. 53 tumours were unselected and 27 specimens were mutator 
phenotype tumours displaying high frequency of microsatellite instability. Among the 
unselected colorectal carcinomas, SMAD4 expression was absent in 20 out of 53 (38%) 
and reduced in another 15 (28%) cases. The immunostaining results of MSI tumours were 
strikingly different from the unselected carcinomas (p<0.0009, Fisher’s exact test). Of the 
27 MSI cancers 26 (96 %) showed SMAD4 expression comparable with normal tissue. In 
our series 21 out of 25 tumours available for analysis displayed a protein truncating 
mutation in the TGFßIIR polyA tract as well. 
3.2. LOH analysis of 18q21 region (SMAD4)
Loss of heterozygosity (LOH) analysis was performed using two fluorescent labelled 
microsatellite markers (18S1156 and D18S363). There were 28 unselected tumours 
available for the study. LOH status of the unselected carcinomas did not have an effect on 
the SMAD4 immunostaining result. 15 tumors out of 22 (68%) displayed evidence of 
deletions. Deletions were equally present in tumours with reduced and normal SMAD4 
staining.  
3.3. TGF-βIIR mutation analysis 
The polyA tract in the coding region of transforming growth factor type II receptor gene 
was scrutinised for deletions by PCR amplification. There were 25 MSI tumours 
available for TGF-βIIR mutation analysis. 21 tumours out of 25 displayed a protein 
truncating mutation in TGF-βIIR polyA tract. The result is consistent with previous 
knowledge that deletions in a polyA microsatellite tract in the coding region of TGF-βIIR 
are characteristic of MSI tumours (Markowitz et al., 1995). 
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4. MICROSATELLITE MUTATIONS AS MOLECULAR TUMOUR CLOCK (V) 
Somatic microsatellite mutations (MS) were demonstrated as a molecular tumour clock. 
Rapid expansion occurred in the xenografts of the mutator cell line. According to low MS 
diversity, the number of divisions varies from dozens to several hundreds. Mutation 
frequencies of about 0.0005 mutations per division, and a doubling time of 24 hours were 
observed in tissue culture of HCT116. This information was used in the tumour clock 
analysis. 
In human MSI+ tumour samples, higher diversity was observed than in the xenografts. 
Usually the diversity was greater in adenomas than in adjacent carcinomas. The diversity 
of allele sizes in human tumours was about eight in adenomas and six in cancers 
compared to a diversity of  about four in the xenografts. 
The diversity nevertheless varied between the adenoma regions, suggesting differences in 
ages. In the adenoma area, divisions from some hundreds to thousands have occurred, 
whereas the carcinoma dots were younger when there were hundreds of divisions. The 
MS alleles of the metastasis of the squamous cell lung cancer were markedly different 
from the alleles of the primary tumour. This suggests that the tumour cells of the 
metastasis represent a proportion less than 1% of the primary tumour, or further mitotic 
activity and evolution after metastasis. At the same time, the distinct difference in allele 
sizes in metastasis compared to the primary tumour suggests that there is  mitotic activity 
during dormancy.  
5. POLYA-DELETIONS IN HNPCC TUMOURS (VI) 
Somatic deletions were present in all four polyA loci (BAT20, BAT25, BAT26, and 
BAT40) in the HNPCC adenomas and cancers. The sum of deletions over the four poly-
A loci ranged from -26 to -49 bases with overlap between adenomas and cancers. 
Adenomas displayed 85% of the deletions observed in the cancers (average of -32.7 
versus -38.4 bases). There was a slight trend for larger deletions in the larger adenomas, 
whereas among the cancers, fewer deletions were present in higher stage cancers, But the 
differencies were not notable. Some of the HNPCC patients were under surveillance with 
six known intervals (average of 2,1 years) between tumour removal and a prior negative 
clinical examination. Surveillance did not significantly reduce mutations in the polyA 
sequences because tumours removed after negative clinical examinations had average 
deletions of -34.8 bases versus -36.5 (P = 0.66) for tumors removed without prior 
surveillance. PolyA deletions were similar between HNPCC adenomas and cancers, and 
between tumours regardless of clinical surveillance. 
Phenotypic differencies between adenomas and cancers seem to have relatively minor 
effects on the length of polyA repeats, which suggests that most MS mutations 
accumulate in phenotypically normal progenitors having about similar proliferation rates. 
The current polyA sequence analysis is not formally quantitative, but polyA-repeat 
mutation patterns support the conclusion that loss of MMR often precedes a gatekeeper 
mutation. 
47
DISCUSSION 
1. FREQUENCY AND SCREENING OF HNPCC (I, II, III) 
1.1. Frequency of HNPCC 
There has been great variation in the estimations of HNPCC frequency. The incidence 
figures have previously ranged from 0,5 to 13 % (Cannon-Albright et al., 1988; Houlston 
et al., 1992; Aaltonen et al., 1994; Bodmer et al., 1994). Estimations were non-molecular 
and based on family history and clinical investigation. Possible reasons for the low 
numbers are lack of coverage in the studies or missed cases. However, low frequency 
figures may be real because of normal variation. In higher estimations poor anamnestic 
information may have raised the figures. The main reason for the great variety among the 
estimations was the fact that no systematic population-based studies were carried out. 
Our study was planned to determine the best strategy for diagnosing HNPCC on a 
population-wide scale. Fresh tissue colorectal cancer specimes were prospectively 
collected from 9 hospitals in central and eastern Finland (two university hospitals and 
seven regional hospitals), representing area of about 1/3 of the Finnish population. The 
real coverage from all operated colorectal cancers was considered to be about 60% in that 
area. 
In the two-phase study there were altogether 1044 colorectal carcinoma samples available 
(509 from Study I and 535 from Study II).  Cancer specimens were screened for 
microsatellite instability utilizing microsatellite marker BAT26. All the patients with 
MSI-H tumours were screened for MLH1 And MSH2 mutations by sequencing of the 
coding regions and exon-intron bounderies. Furthermore all the patients were studied for 
the two Finnish founder mutations. Among 1044 patients 129 (12%) had a MSI-H 
colorectal cancer. Of these, 28 had germline mutation: 26 were MLH1 mutations and two 
MSH2 mutations. The HNPCC incidence associated with MLH1 and MSH2 mutations in 
Finland was determined to be 2.7 % (28 out of 1044 cases). 
1.2. Diagnostic criteria of HNPCC 
The Amsterdam criteria were created for the identification of HNPCC patients (Vasen et 
al., 1991; Vasen et al., 1999), and these criteria are good when proper family history is 
available. In the  "classical" HNPCC families MLH1 and MSH2 genes are usually altered 
(Peltomäki P, 2003), These families usually also fulfil Amsterdam criteria I or II. and the 
tumours in these families show high frequency of MSI. The clinical status in the families 
with MSH6 or PMS2 mutations may be less typical (Peltomäki P, 2003). At least in some 
cases low frequency of MSI is connected to MSH6 (Wijnen et al., 1999; Berends et al., 
2002). 
Amsterdam criteria I (61%) and II (78%)(Table 4) have relatively poor sensitivity in 
identifying HNPCC patients, but Bethesda criteria (Table 5) are most sensitive (94%) in 
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detecting patients (Syngal et al., 2000). However, the proper anamnestic information is 
not available to fulfil the criteria. We have tested three high-risk criteria to find out 
criteria for daily clinical practice. The criteria were retsospectively used on 509 patients 
of study I and prospectively on 535 patients of study II. The evaluated three main high-
risk criteria were:   1) age under 50,   2) a previous or synchronous colorectal or 
endometrial cancer or   3) one first-degree relative with colorectal or endometrial cancer. 
Among patients fulfilling one or more of these high risk criteria (23%), MSI analysis 
identified 22.6% as MSI-H (5% of all cases) and 96% of all MLH1 or MSH2 mutations 
were identified in this small subgroup. This allows us to propose a scenario for HNPCC 
diagnosis in which only high-risk patients are studied for MSI, and only those with MSI-
H tumours are subjected to mutational analysis. 
1.3. Diagnostic methods of HNPCC 
MSI molecular testing has been shown to be a useful method for HNPCC screening in 
suspected cases (Umar et al., 2004). However, MSI test is not specific according to 
different MMR genes.  
At the same time with MSI testing also immunohistochemistry has been investigated as 
screening method for HNPCC. There have been multiple commercial antibodies available 
for MLH1 and MSH2 immunohistochemistry. It was therefore,  necessary to test 
detection abilities of these antibodies.  
For the international study a series of colorectal cancer specimens were collected from 
different international Institutions by the coordinators, including tumours with known 
presence or absence of MSI and DNA mismatch repair enzyme (MLH1, MSH) mutation. 
Each center used its own staining protocol and own antibody dilution, but analyzed the 
slides and scored the staining results according to the recommended scoring system.. 
Each center returned the stained slides, their interpretation of the results and their staining 
protocols to a central representative. 
Re-review of the returned immunostained slides showed great variation in the results, 
lack of internal control, patchy staining, or faint color, especially with MLH1 antibody. 
Only four centers gave a good discriminatory result in MLH1 staining. All the four 
centers have used the same MLH1 as well as MSH2 antibodies, although their protocols 
were different. According to the staining result of these four laborattories, the 
recommended antibodies and protocols were determined. 
According to the result of Study IIIA, recommended monoclonal MLH1 and MSH2 
antibodies were chosen for diagnostic practice at the Department of Pathology, Haartman 
Institute (Department of Laboratory Diagnostics, Helsinki University Hospital). 
Additionally MSH6 antibody was included in the diagnostic antibody panel. Altogether 
174 HNPCC-suspected tumour samples were available for MLH1, MSH2 and MSH6 
immunohistochemistry. MSI analysis was performed at the Department of Medical 
Genetics Haartman Institute after receiving immunohistochemical report of the sample.  
32 out of 35 carcinomas displaying loss of protein expression showed high grade of 
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microsatellite instability (MSI-H). 21 tumours displayed loss of MLH1 expression, as did 
all eight MSH2 tumours, too. Also all three cases, displaying loss of MSH6 expression, 
showed MSI-H, although MSH6 mutation is connected also to low frequency of MSI 
(MSI-L).
Gene testing has been available for most Finnish HNPCC families affected by one of the 
Finnish MLH1 founder mutations. For non-founder cases, time-consuming and expensive 
gene sequencing is needed. Since immunohistochemistry has been available, and loss of 
MMR protein expression is seen, further investigation can be directed at suspect MMR 
genes. As a screening method, MSI analysis is more time-consuming than IHC, and can 
be performed only in specialized laboratories. In some international studies some 
mutation-positive tumours have shown patchy protein expression by either MLH1 or 
MSH2 antibody. Also in our study (IIIB) there were two colorectal tumours displaying 
normal MMR expression, but showing MSI-H.  In these cases, an MSI test is still needed 
to confirm suspicion for HNPCC.  
The results of an international collaborative study (IIIA) and the experiences in our 
laboratory (IIIB) have demonstrated immunohistochemical HNPCC diagnosis to have 
good discriminatory capacity. This is true when recommendations for antibodies and 
protocols are followed. IHC is also a rapid, cost-effecient method, and available in most 
histopathological laboratories 
If loss of protein expression is noted, the patient should have access to genetic counseling 
and genetic testing (Aktan-Collan et al., 2000). This possibility should be offered to the 
patient´s family members as well. At the same time, the possibility for a regular 
colonoscopy should be offered (Järvinen et al., 2000) Regular gynaecological 
investigations should be available for female patients and healthy mutation-positive 
female relatives. In the future, parallel with colonoscopy controls and gynaecological 
investigations, possible affection in other extracolonic organs should be notified, as 
several extracolonic organs may be affected in Lynch syndrome II. It has been 
documented that healthy mutation-positive family members have a tendency to 
underestimate the risk of the disease (Aktan-Collan et al., 2001). There is also a 
possibility to misunderstand the test result. It is therefore recommended that predictive 
testing should be offered in conjunction with an organized cancer surveillance program
(Järvinen, Aarnio, 2000; Renkonen-Sinisalo et al., 2000) 
50
2. THE ROLE OF THE DPC4/SMAD4 GENE IN COLORECTAL CANCER (IV) 
For the evaluation of SMAD4 immunohistochemical staining, 80 colorectal cancer 
specimens were available. 53 tumours were unselected and 27 specimens displayed MSI-
H.  Among the unselected colorectal carcinomas, SMAD4 expression was absent in 20 
out of 53 (38%) and reduced in another 15 (28%) cases. Mutation in the SMAD4 gene 
inactivates TGF-β RII signalling and RII-mediated growth inhibition. And in sporadic 
colorectal cancers, loss of SMAD4 expression may play a more prominent role than 
anticipated. It is known that sporadic Dukes C colorectal cancer has a much poorer 
prognosis than Dukes B cancer. However, in a previous study, patients with loss of 18q 
chromosome in Dukes B carcinoma had as poor a prognosis as did the Dukes C cancer 
patients (Jen et al., 1994). SMAD4 gene involvement could explain some part of Dukes B 
cancers. Our data show that a decrease and complete loss of SMAD4 expression is a 
frequent phenomenon in colorectal carcinogenesis. However, lack of correlation between 
LOH and loss of SMAD4 expression remain partly odd. The concordance between 
immunohistochemistry and SMAD4 genetic aberrations and their correlation with 
prognosis require more extensive and systematic evaluation. 
The immunostaining results of MSI tumours were strikingly different from the unselected 
carcinomas. Of the 27 MSI cancers 26 (96 %) showed normal SMAD4 expression. In our 
series 21 MSI-H tumours out of 25 tumours available for analysis displayed a protein 
truncating mutation in the TGF-ßIIR polyA tract. Transforming factor TGF-β signaling 
inhibits proliferation of normal epithelial cells and has a tumour inhibitory effect in the 
intestine (Alexandrow, Moses, 1995; Heldin et al., 1997). A loss of growth inhibitory 
response to TGF-β through loss of a functional receptor or loss of a normal TGF-β
signaling pathway was common in colorectal tumorigenesis. TGF-β expression is 
increased in colorectal adenomas and carcinomas in addition to a decreased TGF-β RII
receptor level. Inactivation of type II TGF-β receptor was also a common feature of 
HNPCC tumours. These mutations cluster in microsatellite-like polyA repeats in the 
TGF-β RII gene. It is therefore understandable that in mutator phenotype tumours of our 
study, loss of the SMAD4 gene does not play an important role, because both SMAD4 
and TGF-β RII contribute tumour-suppressive effects as members of the TGF-β
signalling pathway (Hahn et al., 1996).  
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3. EVALUATION OF THE TEMPO OF TUMOUR GROWTH USING MICRO-
SATELLITE AS A MOLECULAR TUMOUR CLOCK. AND THE EVALUATION OF 
THE MOMENT OF THE LOSS OF MMR FUNCTION IN CARCINOGENESIS (V, VI) 
Somatic microsatellite mutations provide a method for estimating the time needed for 
normal epithelial cells to develop into a malignant tumour. Time estimation is possible by 
using mutator phenotype (HNPCC) tumours as the mutation frequency is accelerated 
enough in HNPCC tumours to allow evaluation of MS diversity in the tumour cells 
(Shibata et al., 1994; Bhattacharyya et al., 1995). In sporadic tumours, the mutation rate 
is too slow for calculating the tempo of tumour growth. 
In this way mutator phenotype tumours (HNPCC) provide a model for time estimation by 
using microsatellite patterns of the colorectal tumours as a molecular tumour clock.  
The mutations present in both adenomas and cancers are generally “early” mutations, 
whereas “late” mutations are found more frequently in cancers. The extensive MSI 
observed in HNPCC adenomas and carcinomas suggests that loss of mismatch repair 
function was an early occurrence in colorectal tumour progression (Fujiwara et al., 1998). 
Microsatellite mutations may accumulate in MMR-deficient tissues, which can remain 
phenotypically normal. Mutations may accumulate even before the onset of visible 
neoplasia (Calabrese et al., 2004). Later clonal expansion in the cell population will make 
transformation visible. We should therefore be better aware of tiny morphological 
changes in diagnostic pathology. 
Such changes could be small nuclear stratification areas in hyperplastic polyps. Also 
more attention should be paid to differential diagnosis between a hyperplastic polyp and a 
serrated adenoma, as serrated adenomas are obviously underdiagnosed. More information 
is also needed about large Peutz-Jeghers polyps in which nuclear stratification of the 
nucleus is seen in tall hyperplastic epithelia and pseudoinvasion into the muscle wall of 
the gut. Such changes are nevertheless considered to be fully benign. 
In tumour evolution “ dead ends” and missing links are just as natural as in studies of 
mammalian evolution. Microscopic evaluation allows us to look at some of these possible 
“ dead ends” by recognizing distinct morphological areas, and genetic investigation can 
verify persistent cell lineages (Figure 4). 
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Normal epithelia        Adenoma or cancer 
A
B
C
Figure 4. Multilineage progression models of adenoma and cancer cell lineages. 
A. Late divergence of cell lineages. B. Two early lineages. C. Evolution of multiple cell 
divergence and “ dead ends”. 
Genetic comparison of adjacent adenoma–carcinoma tumours makes it possible to 
investigate lineage divergence, which traces persistent lineages (Tsao et al., 1999). DNA 
mismatch-deficient tumours offer an opportunity to study the timing of lineage 
divergence in cell populations, as in HNPCC tumours the mutation rate is rapid enough to 
monitor tumour evolution. The path from cancer cell lineage to carcinoma may not 
require macroscopic expansion before transformation, and adenoma precursors may not 
be necessary for the development of carcinoma. Furthermore, a visible adenoma lesion 
may not be necessary in the pathway to cancer. Usually, however, the diversity was 
higher in adenomas than in adjacent carcinomas. This is consistent with the idea that 
adenomas precede carcinomas. 
The APC gene has played a key role in tumour progression in the colorectum. 
After the tumour suppressor gene APC was discovered, somatic APC mutations were 
believed to occur in the majority of sporadic colorectal tumours, and not only in familial 
adenomatous polyposis coli (FAP) cases.  Complete APC inactivation has been found in 
the earliest neoplastic lesions (aberrant crypt foci, ACF) in the colorectum (Kinzler, 
Vogelstein, 1996). Because of their initiative role in tumorigenesis, the gene is called a “ 
gatekeeper”.  However, by using polyA repeat sequences as a molecular tumour clock in 
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HNPCC tumours, it was discovered that the missmatch repair (MMR) gene might be 
affected before a gatekeeper gene. 
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CONCLUSIONS 
The number of identified HNPCC families is on the increase. The affected patients are 
more aware of the possibility of inherited cancer. At the same time, diagnostic methods 
have become available, and they are more accurate than before. Also colorectal cancer 
patients and family members without a family history may want to know about not 
having an increased risk for malignancy. Microsatellite analysis has previously been the 
method of choice in indicating suspicion of HNPCC. The next diagnostic step has been 
genetic testing, if available. In Finland the Finnish MLH1 founder mutations (mut 1 and 
mut 2) have been tested first. The majority of HNPCC families in Finland are affected by 
one of the Finnish founder mutations. Obvious clinical HNPCC cases with a negative test 
result have been problematic. Other MLH1 mutations could have been found by 
sequencing of the MLH1 gene. Genetic sequencing is nevertheless a very costly method, 
especially if there is no clue about the affected gene beforehand. Therefore all MSH2 or 
MSH6 mutations may not have been found.  
For HNPCC screening three high-risk criteria were evaluated:   1) age under 50 years,   2) 
a previous or synchronous colorectal or endometrial cancer or   3) one first-degree 
relative with colorectal or endometrial cancer. By using these criteria nearly all (96%) 
patients positive for a germline mutation in MLH1 and MSH2 were detected. Therefore 
we can recommend them for clinical practice, especially when only limited family history 
is available. 
At the moment, immunohistochemistry is the first diagnostic choice for suspected cases. 
IHC is also cost-efficient compared to MSI analysis, and especially compared to genetic 
analyses. However, HNPCC-IHC should not be included in routine histological practice, 
unless proper genetic counselling is available for the patients. The positive result in 
immunohistochemistry (loss of MMR protein expression) refers to microsatellite 
instability and also points to an affected gene. It is also a fast method and available in 
nearly every histopathological laboratory. However, there have been few cases/tumours 
displaying MSI-H and normal protein expression at the same time. Therefore MSI 
analyses still have a role in HNPCC diagnostics. 
An involment of SMAD4 gene could have more important role in colorectal 
carcinogenesis than anticipated beforehand. We have seen that loss of SMAD protein 
expression is a frequent phenomenon in colorectal carcinomas. However, there was no 
direct correlation between LOH analysis of 18q21 region and loss of SMAD4 expression 
in our study. In sporadic colorectal cancer, loss of chromosome 18q may indicate a 
poorer prognosis for Dukes B cancer patients than to the patients without loss of 18q, but 
larger studies will be needed to evaluate the prognostic significance of SMAD4 
immunohistochemistry specifically. 
The tumour clock analysis can genetically identify the steps in tumour progression, and 
estimate the number of divisions that have occurred between the steps. It gives 
information about the genetic lineage of the tumour cells. Even though the method is 
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rather rough, there are not many competing alternatives. The time estimation of human 
tumours in vivo by alternative methods presents ethical as well as experimental problems. 
The adenoma-carcinoma sequence is usually described as a linear multistep progression 
from the first morphological change in colorectal crypt epithelia to the final malignant 
tumour. The assumed genetic changes are followed by morphological changes.  
However, it is assumed that in multi-lineage progression divergence may occur early, 
even before visible changes. Loss of the MMR gene cannot be detected in microscopic 
examination before loss of the gatekeeper (APC ), as no visible lesions are present. PolyA 
repeat sequences have properties of a molecular clock in different MMR-deficient 
tumours. The phenotypic differences between adenomas and cancers do not have much 
effect on the polyA profile. Our results show very early loss of the MMR function. MS 
mutations may accumulate in phenotypically normal epithelia, indicating mutations 
before a gatekeeper. 
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